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System Pharmacology and Its Role in P-L-ODAP Pathology and Glutathione
Synthesis
^
Research advisor: Richard J. Bridges, Ph.D.
In addition to the well-characterized sodium-dependent excitatory amino acid
transporters (EAATs) present in the mammalian CNS, a chloride-dependent, sodiumindependent transporter has also been identified that is capable of mediating the uptake of
L-glutamate. Named system x ,, this transporter is an obligate exchanger that normally
couples the export of intracellular L-glutamate with the import of extracellular L-cystine.
Using the human tumor cell line SNB-19 that expresses high levels of system x.., we used
a fluorescent-based assay that allowed system x^ -mediated exchange of L-glutamate and
L-cystine to be followed in real time to assess substrate activity. Interestingly, those
compounds that proved to be the most potent competitive inhibitors (e.g. L-quisqualate
and 4-S-CPG) also proved to be the least active as substrates, suggesting that distinct
structural features may control binding and translocation. In the second portion of work
we studied the neiirotoxic compoimd P-N-oxalyl-L-a,P-diaminopropionic acid (P-LODAP) and its action at system x^. P-L-ODAP is found in the seeds of LatAyrw.;
(chickling peas) and is thought to be an active agent in human lathyrism. We
investigated the action of P-L-ODAP and a series of isomers and homologues at the
chloride-dependent L-glutamate transporter through [^H]-L-glutamate uptake assays. PL-ODAP produced levels of inhibition similar to what is found in the presence of
endogenous substrate L-cystine while the two isomers, P-D-ODAP and a-L-ODAP,
along with the homologues y-L-ODAB and y-D-ODAB proved to be relatively inactive.
A more extensive kinetic analysis revealed P-L-ODAP to be a competitive inhibitor of
chloride-dependent L-glutamate uptake and a substrate at system x, with activity
comparable to L-cystine. Lastly, we investigated the relationship between levels of
system x^ activity and the maintenance of intracellular glutathione concentrations in
several glioma-deiived cell lines. By comparing the effect of system x^ inhibitors, such
as 4-S-carboxyphenylglycine, with other inhibitors of glutathione biosynthesis, such as
buthionine sulfoximine, on glutathione levels, the contribution of the transporter in
supplying extracellular precursors for this antioxidant can be estimated. We observed
that inhibition of system x^ led to a time-dependent decrease in intracellular glutathione
levels. However, we also found that the levels of x^ activity varied among the cell lines,
even though the rates of glutathione utilization appeared similar. These results suggest
that the amount of cystine transported through system x, for glutathione maintenance
may vary between the glioma cell lines.
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Chapter 1: Background and Introduction

Glutamate is a biologically important amino acid which can be oxidized to form
a-ketoglutarate and participate in the Krebs cycle or used as a component in the
biosynthesis of proteins. With a pK^Rp^,,) = 4.07, a pK(,._cooH) = 2.10, and pK(g_NH3+) =
9.47, glutamate is an acidic amino acid that carriers an overall negative charge at pH =
7.4 (Zubay, 1996). The L-glutamate enantiomer is the predominant form found in
biological systems and is the main excitatory amino acid in the mammalian CNS that
participates in fast synaptic communication, as well as more complex signal processes
needed in learning and memory (Cotman et al., 1995).

Excitoto/y wMfMO ocW receptor.;

Upon release into the synapse, L-glutamate sends its message by activating
various ionotropic and metabotropic receptors. Three classes of ionotropic receptors
have been identified and named after the selective agonists used in their discovery: Nmethyl-D-aspartate (NM D A), kainate (KA), and a-amino-3-hydroxy-5-methyl-4isoxazole propionate (AMPA) (Cotman etal., 1995). Kainate and AMPA receptors gate
primarily a Na"" current following ligand stimulation, while N-methyl-D-aspartate
(NMDA) receptors are permeable to both Na^ and Ca^ ions. The movement of Ca^ ions
through the NMDA receptor is an important component in more complex signaling
processes, such as long term potentiation and developmental plasticity (Cotman et al.,
1995). The metabotropic receptors are G protein-coupled and contain eight known
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subtypes that have been divided into three separate groups based on pharmaqological
specificity (Pin and Duvoisin, 1995). The subtypes mGluRl and mGluR5 are Group I
receptors coupled to the Gq protein. When activated, Gq subunits subsequently increase
phospholipase C activity and increase inositol triphosphate levels (Masu, 1991). Group II
includes mGluR2 and mGluR3 receptors and Group III contains mGluR4, mGluR6,
mGluR7, and mGluRS sub^^pes. These latter two groups are directly coupled to the G;
protein complex. When activated, a G; subunit inhibits adenylate cyclase activity that
subsequently reduces the conversion of ATP into adenosine 5-monophosphate (cAMP)
(Genazzani et al., 1993).

Three processes may contribute to the termination of post-synaptic L-glutamate
excitatory signals: diffusion, enzymatic degradation, and transportation out of the
synaptic cleft. Enzymes for L-glutamate degradation are not present in the synapse and
studies by Clements (1992) indicated that changes in synaptic levels of l-glutamate
cannot be solely attributable to diffusion. Thus movement of L-glutamate out of the
synapse by transport proteins is felt to be a m^or contributor to the termination of EAA
signals, replenishment of astrocytic L-glutamate pools, and the prevention of the
overstimulation of ionotropic L-glutamate receptors (Takahashi et al., 1997), Five highafflnity sodhim-dependent L-glutamate transporters have been characterized in humans
and are members of system x*o. These proteins are placed into the solute carrier 1
(SLCl) gene category which includes two isoforms of system ASC, the Na^-dependent
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neutral amino acid transport system. Glutamate aspartate transporter 1 (GLASTl),
predominantly found on glial cells, was first isolated from rat brain and found to have a
weight of 66-KDa (Storck, 1992). Following immunoscreening with an antibody
generated against a 64-KDa protein, glutamate transporter 1 (G L T l) was originally
identified from a rat brain cDNA library (Pines, 1992). The isolation of 3,442-base-pair
cDNA from rabbit small intestine led to the characterization of the excitatory amino acid
carrier 1 (EAACl) (Kanai et al., 1992). Homologues for GLAST, G L T l, and EAACl
were later cloned from the human cortex and named excitatory amino acid transporters 1,
2, and 3 respectively (E A A T l, EAAT2, and EAAT3) (Arriza et al., 1994). Two other
high affinity Na^-dependent L-glutamate transporters were later cloned from a human
cDNA library. EAAT4 is the predominant form in cerebellar slices and EAATS is
present in the mammalian retina (Fairman et al., 1995; Arriza, et al., 1997).
The high-affinity, sodium-dependent l-glutamate transporters are dependent upon
an extracellular electrochemical Na^ gradient established by membrane bound (Na^+K^)ATPases. These transporters utilize free energy stored in the charge and concentration
separation of Na^ and K* ions and cotransport one glutamate molecule, 3 Na^ ions, and
one proton into the cell with subsequent efflux of one

ion out of the cell (Kanner et al.,

1982; Wadiche et al., 1995). During ischemic events when Na* gradients are abolished,
1—glutamate transport is seriously compromised. Extracellular L-glutamate levels may
actually rise due to efflux of 1—glutamate through Na^-dependent transporters (Koch et
al., 1999; Rossi et al., 2(XX)). Excessive levels of L-glutamate in the synaptic cleft can
overstimulate ionotropic EAA receptors and lead to subsequent neuronal death; a
phenomenon termed excitotoxicity (Choi, 1994). Acute forms of excitotoxicity are
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believed to occur following head trauma, stroke, and seizure activity. Pathological
findings in chronic neurological disorders also show selective neuronal loss through
excitotoxic damage (Choi, 1988; Leigh et al., 1996). Some chronic CNS diseases
include: Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis
(ALS).

ChkrWe-e/gpgWent g/wtomarg fra/wport

The high afflnity uptake of L-glutamate can also occur by a second system which
is Na^-independent and Cl -dependent. Initial characterization of this transport system
was performed in a rat astrocytoma cell line (Waniewski and Martin, 1984). In the
LRM55 cells, 35% of high-affinity L-glutamate uptake was mediated by this transporter.
Earlier work following the binding of [^H]-L-glutamate in synaptic plasma membranes
revealed an L-glutamate binding site which was potently inhibited by 2-amino-4phosphonobutyric acid (AP4), L-a-aminoadipate, and quisqualate and relied heavily
upon Cl and Ca^ (Fagg etal., 1982). Later, L-glutamate binding studies in rat astrocyte
membranes helped elucidate a site which was Cl -dependent, Ca^ insensitive, and
inhibited by L-a-aminoadipate and quisqualate but not AP4 (Bridges et al., 1987).
Autoradiography studies in rat brain slices delineated a Cl -dependent L-glutamate
binding site which was also inhibited by L-a-aminoadipate and quisqualate but relatively
insensitive to AP4 (Anderson et al., 1990). The differences in ionic sensitivity and
pharmacological profiles between the three independent studies may represent binding
site subtypes or differences in methods used. However, studies in hippocampal slices and
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synapüc plasma membranes highlight similarities between the high-afflnity chloride
dependent L-glntamate transport system and the earlier characterized Cl -dependent,
osmotically sensitive L-glutamate binding site. Osmotic sensitivity, the ability of low
temperatures to abolish Cl -dependent L-glutamate binding, and the visual presence of
vesicles in synaptic membranes all suggested that the Cl -dependent L-glutamate binding
site and the high affinity Cl -dependent L-glutamate transporter were mediated by the
same or closely related protein (Pin et al., 1984; Bridges et al., 1986). The link between

f H]-L-glutamate binding and L-cystine was established when L-cystine was shown both
to inhibit 80% of Cl -dependent L-glutamate binding in synaptic membranes and to
stimulate glutamate efflux in transport experiments (Kessler etal., 1987).

The coupled transport of cystine and glutamate by a Na^-independent transporter
termed system x,. was first described in human diploid fibroblasts. The conclusion that
glutamate and cystine were intracellularly accumulated by the same transporter was
supported by a number of observations. First L-cystine and L-glutamate mutually
inhibited the transport of each other in initial velocity uptake experiments under chloridedependent conditions. Second the K„ for L-cystine uptake was similar to the inhibitory
K; value of L-cystine on L-glutamate uptake and vice

Finally, pharmacological

assays of various amino acids produced similar levels of inhibition or lack thereof on
both L-cystine and L-glutamate uptake (Bannai and Kitamura, 1980). A subsequent
study estimated L-cystine and L-glutamate to possess an overall negative one charge at
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physiological pH when transported by the Na^-independent transport system. Potent
inhibitors of system

included DL-a-aminoadipate, DL-a-aminopimelate, and DL-

homocysteate (Bannai and Kitamura, 1981). Later studies in human diploid fibroblasts
showed that in an environment which depleted intracellular L-glutamate levels, Cl dependent L-cystine upake and Cl -dependent L-glutamate transport were both seriously
compromised (Bannai, 1986). Additional experiments in the the same study revealed an
L-cystine induced efflux of L-glutamate of 1.9 nmol/min mg protein and an L-cystine
upake rate of 1.66 nmol/min mg protein. From these studies it was concluded that the Cl
-dependent glutamate/cystine transporter, system Xg, was an anionic exchanger which,
under normal physiological conditions, used a high intracellular L-glutamate
concentration to drive the import of cystine with a concurrent efflux of glutamate. From
the above efflux and transport rates, it appears that cystine influx and glutamate exodus
occiu" at a 1:1 ratio. Under experimental conditions, this transporter is also able to
homoexchange intracellular and extracellular glutamate (Bannai, 1986).
Recent cloning of system x^ has helped elucidate its molecular architecture and
enabled the system to be studied in Xenopwj oocytes (Sato et al., 1999). cRNA prepared
from mouse macrophage cDNA was injected into oocytes. From Cl -dependent L-cystine
uptake studies, it was ascertained that two clones, Cm30 and Dr4, were needed for proper
transport. Cm30 encodes the cell surface glycoprotein 4F2hc. The slightly hydrophobic
4F2hc protein has one transmembrane domain and belongs to the 4F2 group of
transporters which includes system Land y^L. Dr4 encodes the 502 amino acid protein
xCT. This protein has a relative molecular mass of 555 kDa, twelve predicted
transmembrane domains, and is much more hydrophobic than 4F2hc. It is speculated
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that xCT functions as an antiport transporter. 4F2hc and xCT are joined by a critical
sulhydryl linkage to form a heteromuldmeric polypeptide. This polypeptide, when
expressed on the cell surface, forms system x^ (Figure 12). However, recent studies
have also shown the transient expression of system x^ in oocytes transfected with xCT
and rBAT cDNA (Wang et al., 2003).
Recent cloning in a human undifferentiated teratocarcinoma cell line, NT2,
yielded a sequence termed SLC7A11 which encodes the putative 501-amino acid protein,
hxCT, that shares 89% identity with mouse xCT (Bassi et al., 2(X)1). Cloning in human
fibroblasts has been reported to yield two cDNA clones for xCT. Clone 1 cDNA
contained 1861 ribonucleotides while clone 2 cDNA contained 5626. The last 925
ribonucleotides of clone 1 are identical to the first 925 ribonucleotides of clone 2.
Approximately ninety percent of seqiience homology is shared between the putative 501
amino acid protein translated from clone 1 and mouse xCT (Sato, 2000). In the human
retinal pigment epithelial cell line, ARPE-19, a 2482 bp-long cDNA segment was
isolated. The encoded xCT protein from the ARPE-19 clone shares 89% sequence
identity with mouse xCT (Bridges et al., 2001). In the human glioma cell line U87
treated with DEM, a 2000 bp cDNA clone for xCT was found. When compared to mouse
xCT, the encoded protein, hxCTb, shared 86% amino acid sequence identity (Kim et al.,

2001).
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Trwwporf o/rofe

G5H b(OjyMfAg.rû

The physiological importance ôf system x, was explored by studying the
metabolic conversions of glutamate and cystine following transport into human diploid
fibroblasts (Bannai and Kitamura, 1980). Fbllowing a two minute uptake study, the
majority of [^Hj-L-cysdne was recovered as L-cysteine and glutathione whereas 95% of
L-glutamate remained unchanged. These biochemical observations along with the
finding that intracellular glutathione levels fall precipitously in L-cystine depleted media
indicate that L-cysdne transport through system x^ may be a rate limiting step in the
biosynthesis of glutathione (Banai et al., 1977). Cystine and its reduced counterpart Lcysteine are brought into the cell through other transporters. Transport of cysteine
through the sodium-dependent transport system ASC and the sodium-independent system
L has been observed (Bannai, 1984 and Shanker, 2(X)1). Cysteine transport into cultured
primary astrocytes and neurons by system x*,- has also been reported (Shanker, 2001).
EAATS when expressed in Xenopi» oocytes transported L-cysteine with a K^ of 190 piM
(Zerangue et al., 1996). In rat alveolar type II cells, cystine transport was largely by
system x^o (Knickelbein et al., 1997). In human endothelial and pancreatic cells, Lcystine was found to be transported by y-glutamyl transpeptidase (Cotgreave et al., 1994;
Sweiry et al, 1995).

G/wWAfOMg cyc/g

Glutathione is the m^or mammalian cell thiol that serves in the storage and
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transport of cysteine and is a key intermediate in a wide range of biochemical processes.
Acting as a nucleophile, it can reduce ribonucleotides into deoxyribonucleotides and help
in maintaining other antioxidants such as ascorbate and a-tocopherol in their reduced
states. GSH can act directly or enzymatically with GSH peroxidases and GSH Stransferases in the neutralization of reactive oxygen species, free radicals, and
electrophiles. GSH directly coiyugates with various drugs and endogenous molecules
and assists in their metabolism (Meister, 1985).
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine and is
synthesized by two energy-dependent enzymatically coupled reactions (Rgure 1.1). LGlutamate and L-cysteine are first joined through the action of y-glutamylcysteine
synthetase. This step is inhibited by both GSH and L-buthionine-[S,R]-sulfoximine
(Griffith and Meister, 1979). The second step, catalyzed by GSH synthetase, adds Lglycine to y-glutamylcysteine to form GSH. The breakdown of GSH or GSSG occurs in
the presence of y-glutamyl transpeptidase. This enzyme is located predominately on the
extracellular side of the plasma membrane. The degradation occurs enzymatically by yglutamyl transpeptidase bringing an acceptor into proximity with the y-glutamyl group.
Some acceptors include amino acids and water. The y-glutamyl-amino acid is transported
into the cell and cleaved by y-glutamyl cyclotransferase. The amino acid is freed and the
y-glutamyl moiety is converted to the ring structure 5-oxoproline (Meister, 1989). Due to
the stability of the amide bond in 5-oxoproline, the conversion of this five member ring
into L-glutamate requires ATP and the enzyme 5-oxoprolinase. L-2-Oxothiazolidine-4carboxylate, an exogenous substrate for 5-oxoprolinase, is converted to L-cysteine in the
presence of enzyme. The last step of the y-glutamyl cycle includes the cleavage of
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cysteinylglycine into individual cysteine and glycine molecules by dipeptiduse (Meister,
1991; Meister et al., 1983).

Trwwport q/cyjrine by jyffg/n x /

o rote Zimiring Jtep m

b(Ojynrbg.rir

Lowered extracellular L-cystine levels and inhibition of L-cystine uptake by Lglutamate separately decreased intracellular GSH levels in the neuronal hybridoma cell
line N 18-RE-105. This led to cell lysis and suggested the importance of L-cystine uptake
through system Xc for maintenance of intracellular GSH levels (Murphy et al., 1989).
Later studies in immature cortical neurons showed L-cystine transport to be blocked with
subsequent cell death by system Xg inhibitors quisqualate, homocysteate, ibotenate, and
L-glutamate (Murphy et al., 1990). In the rat glioma cell line C6, a lOh incubation with
excess glutamate or media with a low cystine concentration precipitously decreased
intracellular GSH levels (Cho and Bannai, 1990). Increasing the L-cystine amotmt in the
presence of a high L-glutamate concentration restored GSH levels. These results provide
another example of the role of system x, in GSH maintenance. However, following
separation of a rat neuronal-glial coculture, glial intracellular GSH levels were
maintained by L-cystine, whereas neuronal GSH levels were sustained by uptake of Lcysteine released from the glial cells (Sagara et al., 1993). Consistent with Sagara's
flndings, it was found that intracellular GSH levels in rat primary neuronal cells were
maintained by transport of extracellular L-cysteine (Kranich et al., 1996).
Early work in our lab has led to an extensive pharmacological proflle of Cl dependent L-glutamate uptake in LRM55 cells (Patel et al., 2004). From the initial
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11
inhibition studies,

determinations were made on several of the most potent inhibitors.

It was further ascertained that these compounds were competitive inhibitors. The third
chapter in my work deal^ with further elucidation of the action of these compounds at
system Xg. By modifying a fluorometric assay first developed by Nicholls to measure I—
glutamate efflux from synaptosomes, ionic dependency of L-cystine induced L-glutamate
efflux was explored. Following this, the competitive inhibitors were analyzed for their
ability to stimulate L-glutamate efflux as should occur in heteroexchange. Comparisons
between the rate of L-glutamate efflux in the presence of the endogenous system Xg
substrate L-cystine with those rates induced by the competitive inhibitors allowed these
compounds to be classified as either substrates, partial substrates, or non-transportable
inhibitors. The second portion of work focuses on establishing the activity of p-L-ODAP
at system Xg. This glutamate analogue is generally accepted as the causative agent in
motor neuron degeneration following consumption of seeds from plants belonging to the
genus. Cl-Dependent [^H]-L-glutamate uptake and the recently modified
fluorometric assay were used as tools to determine the kinetic properties and substrate
properties of P-L-ODAP. P-L-ODAP was found to be a competitive inhibitor at system
Xg with a Kj around 100 pM. This non-protein amino acid also produced an L-glutamate
efflux rate that was comparable to that mediated by L-cystine. These findings may
further elucidate the biochemical role P-L-ODAP plays in neurological pathologies
associated with lathyrism. The last portion of my work focuses on the relationship
between Cl -dependent L-glutamate uptake activity and maintenance of GSH levels in
human glioma cells. A series of four human glioma cell lines were screened for system
Xg activity. Intracellular GSH levels were also measured and compared to the
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values

12

generated in the kinetic studies. It was hypothesized that the intracellular GSH levels in
the cell lines expressing the highest activity of Cl -dependent L-glutamate uptake would
be the most dependent on L-cystine uptake through system x ,. Our findings show that
although the cell line expressing nearly triple the activity of Cl -dependent L-glutamate
uptake had the highest control GSH level, maintenance of this antioxidant was least
dependent on L-cystine uptake through system x,' in the SNB-19 ceU line. These cells
appear to possess an alternative mechanism to provide the rate-limiting GSH precursor.
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Figure 1.1. y-Glutamyl Cycle.
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Rgure 12. Schematic representation of the heteromeric amino acid transporters.
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Specific Aims:

I) Develop a fluorometrically-coupled assay to measure real-time I—glutamate efflux
rates and differentiate substrates from non-substrates of system Xg.
a) Elucidate ionic dependence of L-cystine induced L-glutamate efflux.
b) Measure L-glutamate efflux rates in the presence of system Xg inhibitors.

x/

wzff mdwcg L-gWomatg g^nx rotgj tbat w e WtenwWeiJ in the

prejence q / non-iranjportabie inbibitor.;.

Compétitive inbibtiorj^ q/jy^tem Xg wtib fim tiw cbemicoZ jti"wcfwe.r witi bebove
tiijg^rentiy W tbe cy.$tine/gb<rwMWe obtigWo/y excbwiger.

n ) Elucidate the interaction of ± e 1—glutamate analogue P-L-ODAP with system Xg .
a) Assay the action of P-L-ODAP at system Xg by measuring its effect on chloridedependent L-glutamate uptake.
b) Perform a kinetic analysis to elucidate P-L-ODAP's mode of inhibition.
c)

Using the fluorescence assay, determine whether P-L-ODAP is a system Xg
substrate, partial substrate, or non-transportable inhibitor.

/S-L-ODAP is a JKbsti-gte W jyjfem Xg wbicb may provitile a roftie q/^entiy to occwmw/We
fbü newotoxin fnti-ocetiwiwiy anti cfew ti^om tbe .^nqptic cie/r.
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III) Evaluate the relationship between system

activity and maintenance of GSH levels

in human glioma cells.
a) Determine system

activity by measuring

values in a series of four human

glioma cells.
b) Determine GSH turnover in the four cell lines by measuring intracellular GSH
levels following incubation with buthionine sulfoximine.
c) Determine time course changes in intracellular GSH levels following incubation
with the competitive system x, inhibitor 4-S-CPG.
d) Identify potential alternate routes of entry for GSH precursors.

Glioma cell lines with the highest total intracellular GSH levels w ill express the highest
Cf-efgpg/Kfgnt iL-g/wfo/nafg wptoAg octzvify.

znfracgZZw/w G S ff Zeveü in gZzoma ceZk

(ZgpgwZgnr

wpZate actzvzfy wzZZ

the

zAg mojt (ZqpgwZenf on Z,-cyj/fng
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C hapter!: Methods and Materials

CeZZ CwZZwrg

Human glioma cell lines (obtained from American Type Culture Collection
Manassas, V A ) were grown in DMEM/F12 medium (pH 7.4) containing Im M pyruvate,
14.28 mM NaHCOg, 25 mM HEPES and supplemented with 10% fetal bovine serum and
a mixture of penicillin (100 U/ml), streptomycin (100 U/m l), and amphotericin B (0.25
pg/ml). Final concentrations (mM) of amino acids are as follows: L-alanine (0.05),
arginine (0.85), L-asparagine - H^O (0.05), L-aspartic acid (0.05), L-cysteine - H^O
(0.13), L-cystine - 2HCL (0.10), L-glutamate (0.05), L-glutamine (2 3 ), glycine (0.25), Lhistidine HCl - H 2O (0.15), L-isoleucine (0.42), L-leucine (0.45), L-lysine HCl (030), Lmethione (0.12), L-phenylalanine (0.22), L-proline (0.15), L-serine (025), L-threonine
(0.45), L-trypotophan (0.04), L-tyrosine 2Na 2 H^O (0.31), L-valine (0.45). Cell lines
were cultured in 150 cm^ flasks (Coming) and maintained at 37 °C in a humidiOed
atmosphere of 5% CO;. Cells were lifted from the flasks by the addition of 10 ml trypsin
(0.05% final concentration) for 3-5 minutes for passage every three to five days. At this
time cell culture stocks for cryopreservation were prepared by maintaining 1x10^ to 2x10^
cells in DMEM/F12 supplemented with 10% DMSO and storing at -196 °C under liquid
N;. In the fluorometric assays, SNB-19 glioma cells were grown in Ham's F-10 medium
(pH 7.4) containing 1 mM pyruvate and 16 mM NaHCO^ and supplemented with 15%
fetal calf semm. For individual experiments, cells were seeded in 12-well culture plates
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at a density of around 5xl(X*to 2x10^ cells/well and maintained for 3 to 4 days until just
confluent. Two wells per plate were designated as protein wells.

CeZZ Transport A$.;qy

The uptake of glutamate into cultured cells was quantified using a modification of
the procedure described by (Martin, 1979). Individual wells, after removal of culture
media, were rinsed three times and pre-incubated in 1ml HEPES buffered (pH 7.4)
Hank's balanced salt solution (HBHS) at 30 °C for 5 min. Where indicated the HBHS
was altered by ionic substitution to isolate the Na* and Cl -dependent transport systems.
The buffers contained: (1) total (Na^ and Cl -dependent): 137 mM NaCl, 5.1 mM KCl,
0.77 mM KH 2 PO4 , 0 . 7 1 mM MgS0 4 .7 H 2 0 ,T .l mM CaCl;, 10 mM D-glucose, 10 mM
HEPES; (2) Na'^-dependent: 130 mM Na gluconate, 5 mM K gluconate, 1.1 mM Ca
gluconate, 0.77 mM KH 2PO4 , 0.71 mM MgSO^

7

H 2O, 10 mM D-glucose, 10 mM

HEPES and (3) Cl -dependent: 137.5 mM choline Cl, 5.36 mM KCl, 0.77 mM KH 2PO4 ,
0.71 mM MgSO^

7

H 2O, 1.1 mM CaCl;, 10 mM D-glucose, 10 mM HEPES. Uptake

was initiated by aspiration of the preincubation buffer and the addition of a 500 pi aliquot
of the appropriate transport buffer containing [^H]-L-glutamate (10-500 pM, Enal
concentration). In those assays that evaluated inhibitor activity, the 500 pi aliquot of
transport buffer contained both the [^H]-L-glutamate and potential inhibitor to ensure
simultaneous addition.

Following a 5 min incubation at 30 °C, the assays were

terminated by three sequential

1

ml washes with ice cold buffer and then the cells were

dissolved in 1 ml of 0.4 M NaOH for 24 hours. An aliquot (200 pi) was then transferred
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into a 5 ml glass scintillation vial and neutralized with the addition of 5 pi glacial acetic
acid followed by 3.5 ml Liquiscint® scintillation fluid (National Diagnostics) to each
sample. Incorporation of radioactivity was quantified by liquid scintillation counting
(LSC, Beckman LS 6500). Values reported are corrected for non-specific uptake (e.g.,
leakage and binding) by subtracting the amount of |^H]-L-glutamate accumulation at 4
°C. Protein content was determined by the bicinchoninic acid (BCA) method (Pierce)
(Smith et al., 1985). ïünetic constants of substrates and inhibitors were determined using
this same procedure by varying the concentrations of L-glutamate and inhibitors with
respect to

and K, values (for review see (Christensen, 1975).

GSH /{gcyc/mg

The GSH recycling assay introduced here was first reported by Tietze, (1969)
with modifications by Griffith, (1980) and Anderson, (1985). GSH in the presence of
5 3 '-dithiobis(2-nitrobenzoic acid) (DTNB) is oxidized to GSSG with a concurrent
formation of 5-thio-2-nitrobenzoic acid (TNB). GSSG is recycled back to GSH in the
presence of GSH reduct^e and the cofactor NADPH. The stoichiometric formation of
TNB was monitored at A^^^ and is proportional to the total amount of GSH.
A standard curve was run during GSH detection of unknowns. Seven sequential
GSH amounts ranging from 0.039 nmols to 1.25 nmols were added to separate wells
containing 50 pi of DTNB from a 2.4 mM stock, 50 pi of NADPH taken from a 0.8 mM
stock, and 50 pi of GSH reductase taken from a 2.65 U/mL stock. The total volume in
each microplate well was 200 pi and the reaction was initiated by the addition of
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NADPH. DTNB, GSH reductase, and NADPH stock solutions were all made in a stock
buffer at pH 7 3 containing sodium phosphate (143 mM) and Na^-EDTA (6.3 mM). The
microplate was shaken and placed in a Molecular Devices Thermomax microplate reader
with absorbance read at 405 nm by SOFTmaxPRO software (version 12.0) at 10 second
intervals for 5 minutes. Slopes from the series of eight standards were taken and plotted
as a function of GSH amount to generate a standard curve. Slopes from the unknowns
were interpolated Aom a linear fit of thé standard curve to generate calculated amounts.
A background rate was determined in the presence of 50 pi 1%SSA, 50 pi NADPH, 50 pi
DTNB, and 50 pi GSH reductase.
Prior to the harvesting of cells for total GSH detection, 1 mL of 0.4 NaOH was
added to designated protein wells. The cells were dissolved for 24 h and total protein
content was determined via the BCA method. Test wells were rinsed Ix with HBSS. 1%
SSA solution (1 mL) was then added to each well and the cells were lifted by the
scraping action of a flame-bent pasteur pipette. The homogenate was vortexed and
microfuged on high for approximately 1-3 minutes. After one series of freeze/thaw
cycles, 50 pi of supernatant was used for total GSH detection.

f/Mororngtzc

Fluorometric determination of L-glutamate efflux was quantified using a
modification of the procedures described by Nicholls and Shira, (1986) and Vesce et al.,
(1997).

NADPH fluoresence was quantified using a Hitachi F-2000 fluorescence

spectrophotometer fitted with a thermostatted cuvette holder and a 1 cm^ electronically
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driven magnetic stirrer platform. Confluent monolayers of SNB-19 glioma cells grown on
coverslips were paired, placed back to back and rinsed in the appropriate HBHS buffer
for 10 min. The coverslips were transferred and incubated in a stirred quartz cuvette
containing 2 ml HBHS at 30 °C. Assays were initiated with the addition of NADP' (1
mM) at 0 sec followed by GDH (33 U) at 60 sec. Subsequent additions of l^cystine or
other potential substrates (50-500 piM) were made as detailed in the figure legends. Each
experiment was terminated with the addition of Triton X-100 (0.5%) to determine the
total amount of L-glutamate in the cells. The amount of L-glutamate efflux was
determined via a standard curve generated in an identical experiment but omitting the
cells. Following the enzyme, seven sequential additions of 4 nmol L-glutamate were
made yielding a non-linear curve. Rates of L-glutamate efflux are reported as mean ±
S.E.M and are corrected for non-specific efflux (e.g. leakage) by subtracting the amount
of L-glutamate efflux in the absence of L-cystine.

U-373, SW-1088, SNB-19 and CCF-STTGl glioma cell lines were purchased
from American Type Culture Collection (ATCC) (Manassas, V A ). General cell culture
supplies were purchased from Becton Dickinson (Franklin Lakes, NJ), Coming (Coming,
N Y ), and Life Technologies (Grand Island, N Y).

L -[3,4-^H]-Glutamic acid was

purchased from Dupont NEN (Boston, MA). L-Glutamate, L-cystine, L-a-aminoadipate,
D-aspartate, dihydrokmnate, kainate, L-homocysteate, L-homocysteine sulphinate and Lserine-O-sulphate were purchased from Sigma (St. Louis, M O). 2-Amino-2-norbomanecarboxylic

acid

was purchased from

Aldrich

(M ilw aukee, W I). (RS)-4-
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bromohomoibotenate, quisqualate, ibotenate, 4-S-carboxyphenylglycine, p-L-ODAP,
AP4, NM DA and AMPA were purchased from Tocris (Ballwin, MO). (1S,3S)-13homo-ACPD was obtained from Kenneth Curry. L-Ny-P-chlorophenyl-glutamine from
Christopher Sean Esslinger. 2,4-MPDC, L-rrww-2,4-PDC, L-rrwM-23 -PDC and L-onfzgwZo-3,4-MPDC were synthesised as described (Bridges et al., 1991; Bridges et al., 1993;
Bridges et al., 1994; Humphrey et al., 1994; Esslinger et al., 1998). AH other chemicals
were purchased Aom Sigma (St. Louis, MO) and VW R (West Chester, PA).

SratzjfzcoZ A/zaZy.yw

Student t-Tests were performed on the data.

For analyses, two group t-Tests with

unpaired data were used. An F probability of < 0.05 indicated statistically different
variances so a t-Test with unequal variance was performed. An F probability of > 0.05
indicated equal variances so a t-Test with equal variance was performed.
indicated, p <0.05 or p <0.01 were considered significant.
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Chapter 3: Differentiation of Substrate and Non-Substrate Inhibitors of Transport
System x, : an Obligate Exchanger of L-Glutamate and L-Cystine.

Introduction

High-affinity glutamate transporters are credited with numerous functions within
the mammalian central nervous systems (CNS), including roles in: signal termination,
transmitter recycling, excitotoxic protection, and the regulation of extracellular glutamate
levels.

Many of these activities have been ascribed to the excitatory amino acid

transporter (EAAT) subtypes 1-5, which are members of the x^^ family of electrogenic,
Na^-dependent anionic amino acid transporters (for review see: Bridges et al., 1999;
Danbolt, 2001; Palacin et al., 1998). Another transport system, referred to as system x^,
has been identified which is also capable of translocating L-glutamate, yet is readily
distinguished from system x*o', in that it is Na^-independent, Cl -dependent,
electroneutral, and acts as an obligate exchanger of L-glutamate and L-cystine. Recently
cloned from mouse and human cDNA libraries (Bassi et al., 2001; Sato et al., 1999),
system x^ is a member of the newly characterized glycoprotein-associated amino acid
transporter (gpaAT) family (Verrey et al., 2000). The transporters in this family are all
obligate exchangers that must form heterodimers with a glycoprotein subunit (often
referred to as the heavy chain) for functional surface expression. In the instance of
system x ,, the heterodimer is formed between the transporter subunit xCT, a 502 amino
acid containing protein with twelve putative transmembrane domains, and 4F2hc, a cell
surface glycoprotein (initially referred to as CD98 in mouse) that is also associated with
transport systems L and y^L (Sato et al., 1999).
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Rather than function to concentrate L-glutamate intracellularly, this system is
thought to utilize normally high intracellular levels of L-glutamate to drive the import of
L-cystine. Given this directionality, interest has focused on both the movement of
cystine into cells as a precursor for glutathione biosynthesis (McBean, 2002; Sagara et
al., 1993a), as well as the efflux of glutamate out of cells as a potential route leading to
excitotoxic neuronal injury (Barger et al., 2001; Espey et al., 1998; Murphy et al., 1989;
Piani et al., 1994). As expected, system x^ activity can be quantised using either Lglutamate or L-cystine as a substrate, and in both instances, uptake is Cl -dependent and
Na^-independent. Glutamate uptake through this system is competitively inhibited by
cystine and vice verfo (Bannai et al, 1980; Cho et al., 1990). System x, -mediated
transport has been reported to occur in primary cultures of neurons (Sagara et al., 1993b)
and astrocytes (Allen et al., 2001; Gochenauer et al., 2001), C6 glioma cells (Cho et al.,
1990), human gliomas (Ye et al., 1999), retinal Muller cells (Kato et al., 1993), microglia
(Piani et al., 1994), as well as outside the nervous system in fibroblasts, hepatocytes,
alveolar type II cells, macrophages, renal tubule cells, and umbilical vein endothelial
cells (for review of cellular distributions see Ishii et al., 1992).
The amounts of system x,. activity typically found in many standard
neurochemical preparations are relatively low, especially when compared to the levels of
EAAT activity. Indeed, the first indications that system x,. was present in brain can be
traced back to studies quantifying the distribution and pharmacology of Cl -dependent L[^Hj-glutamate binding, rather than studies directly measuring uptake (Anderson et al.,
1990; Bridges et al., 1987a; Bridges et al., 1987b). Advantageously, the identification of
CNS-derived tumor cell lines expressing increased levels of Cl -dependent L-[^H]-
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glutamate uptake allowed the transport system to be more selectively characterized
(Murphy et al., 1989; Waniewski et al., 1984). The resulting pharmacological profiles
from these cell lines are consistent with the activity of system

as characterized in non-

neural tissue, such as fibroblasts (Bannai et al., 1980) and hepatocytes (Takada et al.,
1984). Early work in the Bridges lab has established a pharmacological proEle of potent
competitive inhibitors of Cl -dependent L-glutamate uptake in the rat spinal astrocytoma
cell line, LRM55. In the present work, these competitive inhibitors are evaluated for
substrate specificity with a fluorometric assay that allows the exchange of extracellular Lcysdne with intracellular L-glutamate to be directly followed (Nicholls et al., 1987). In
this manner, competitive blockers can be further classified as either alternative substrates,
such as ibotenate, or non-substrate inhibitors, such as 4-S-carboxyphenylglycine. The
results of this study should prove of value in construcdng a more detailed
pharmacological profile of system x, and identifying analogues with which to investigate
its physiological roles, as well as provide more insight into the complex physiological
acdons of a number of widely udlized glutamate analogues, such as ibotenate and
quisqualate, that appear to interact with this transporter.

Results:

The pharmacological specificity of system x^ was first delineated by
systemadcally assaying EAA analogues (500 ;<M) for their ability to block the
accumuladon of L-[^H]-glutamate (100 /<M) into LRM55 cells under Na^-free condidons
(equimolar replacement with choline) (Patel etal., 2004). The pharmacological profile
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was distinct from both the EAATs and ionotropic receptors. The most potent inhibitors
of the Cl -dependent L-glutamate transporter were the acyclic compounds Lhomocysteate and L-serine-O-sulphate and the cyclic glutamate analogues ibotenate,
(RS)-4^bromohomoibotenate, quisqualate, and 4-S-carboxyphenylglycine (Table 32).
Lineweaver-Burk plots and associated kinetic parameters for transport inhibitors were
estimated by computer analysis using the A.cat kinetic program (BioMetallics Inc.) with
weighting based on constant relative error. A ll six compounds were found to be
competitive inhibitors at system x^ with IQ values ranging from 5 to 50;zM.
The cellular efflux of L-glutamate can be detected fluorometrically by measuring
the conversion of NADP^ to NADPH (excitation 370 nm, emission 450 nm) as the
extracellular L-glutamate is rapidly metabolized by glutamate dehydrogenase (GDH)
included in the assay mixture (Figure 3.1). In contrast to competition assays, in which
the accumulation of a single radiolabeled substratejs followed, this approach allows the
actual exchange of intracellular L-glutamate and extracellular L-cystine by system x^ to
be monitored in real time. Thus, cells are grown on coverslips that are suspended in a
fluorometric cuvette containing assay buffer, GDH, NADI^, and putative
substrates/inhibitors of system x ,. The amount of L-glutamate in the extracellular
compartment is quantified using a standard curve generated with defined aliquots of Lglutamate (4 nmol) added in the absence of cells (Rgure 3 2 , panel A ). The total amount
of L-glutamate remaining in the cells is determined at the end of each assay following
lysis with Triton X-100 (Figure 3.3, panel A and B).
To carry out these exchange experiments, SNB-19 cells, a more recently
identiAed human glioma cell line that exhibits high levels of system x^ activity was used.
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Advantageously, the increased levels of transporter activity provided a greater signal to
noise ratio needed for the efflux studies. Initial experiments quantifying the transport of
L-pH]-glutamate (100 pM) into SNB-19 cells in the presence of Cl and absence of Na''
(equimolar substitution with choline) demonstrated an activity of 824 ± 75 pmol/min mg
protein (n = 3). This represented a little more than 60% of I^[^H]-glutamate uptake
measured in the presence of NaCl (1340 ± 68 pmol/min mg, n = 3). Measurements made
under Cl -free conditions (replacement of Cl with equimolar gluconate) yielded uptake
rates of 577 ± 82 pmol/min mg (n = 3), while the equimolar substitution of sucrose for
NaCl decreased activity to 55** 11 pmol/min mg protein (n = 6). Kinetic analyses (plots
not shown) of the Cl -dependent uptake in the SNB-19 cells yielded K^ and

values

(mean ± SEM, n = 4) for L-glutamate of 111 ± 10 pM and 1410 ± 72 pmol/min mg
protein, respectively.
As depicted in Rgure 3.3, the addition of L-cystine (500 pM) to the fluorometric
cuvette containing the SNB-19 cells (Panel B) resulted in a marked increase in the
appearance of extracellular L-glutamate when compared to control (Panel A). Efflux in
the presence and absence of putative substrates of system x^ was essentially linear over
the time couse of the experiment (1500 sec), with the total intracellular pool of Lglutamate being about 212 ± 0.72 nmol/mg protein (n = 62). Initial experiments also
confirmed that basal levels of eÉlux were not increased by the addition of EAA receptor
agonists NMDA, kainate, and AMPA, or fro/w-ACPD. Similarly, when carried out with
Na^-free buffer, the addition of L-n-ww-2,4-PDC or D-aspartate, two well characterized
substrate inhibitors of the Na^-depepdent EAAT systems, also failed to produce an
increase in the efflux of L-glutamate.
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The ionic dependence with which substrates of system

induced an efflux of L-

glutamate from the SNB-19 cells was also examined (Table 3.1). When the fluorometric
efflux assays were carried out in the presence of both Cl and Na'' the rate of efflux
detected following the addition of L-cystine (initial concentration 250 pM) was 0.61
nmol/min mg protein. Interestingly, when carried out under Na^-free conditions, the rate
of efflux increased by more than 50% to 1.03 nmol/min mg protein, suggesting that some
of the L-glutamate had been recaptured by the cells through the Na^-dependent EAATs
before it could be metabolized by the GDH. Consistent with the Cl -dependence of
system x^, replacement of the Cl with gluconate, markedly reduced the rate of efflux
observed in either the presence or absence of Na''.
The exchange assay was then used to evaluate the potential substrate activity of
those compounds identified as potent competitive inhibitors. These analogues were
evaluated at concentrations approximately 10-fold greater than their observed fQ values
to insure that comparisons were conducted at similar levels of transporter occupancy.
Because the IQ values had been determined in LRM55 cells, the compounds were also
tested at these same concentrations as inhibitors of Cl -dependent L-[^H]glutamate (100
pM) uptake into SNB-19 cells to insure that the relative activities of the compounds did
not change. As reported in Table 3.2, inclusion of the analogues at the concentrations
indicated produced very similar levels of inhibition (88 ± 5%, mean ± SD, n = 7) in the
SNB-19 cells. The resulting rates of efflux produced by the analogues indicated
considerable variation in their suitability to act as substrates for system x ,. For example
ibotenate was able to produce an efflux rate that was comparable to that of L-cystine,
while closely related analogues (RS)-4-bromohomoibotenate and quisqualate showed
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markedly less activity, 55% and 35%, respectively. One of the most potent competitive
inhibitors identified, was 4-S-carboxyphenylglycine and its ability to act as a non
substrate inhibitor was further explored by combining it with L-cystine in the efflux assay
(Figure 3.4). Consistent with its actions as both an effective inhibitor and ineffective
substrate, 4-S-carboxyphenylglycine did not produce an efflux-mediated increase in
fluorescence by itself, but was able to attenuate the L-cysüne-mediated efflux when both
were included in the assay.

Discussion:

The demonstration that EAA receptor agonists commonly used as probes of
excitotoxic pathology, such as L-quisqualate, ibotenate, and L-homocysteate, also act at
system \

raises some interesting interpretational issues regarding the mechanisms

through which these analogues produce CNS damage. On one hand, compounds that act
as substrates of system x^' could potentially increase extracellular levels of L-glutamate
and the likelihood of excitotoxic injury by way of an exchange-mediated efflux. That
this can indeed occur is supported by studies with microglia, where the efflux of Lglutamate through system x,. is thought to underlie the excitotoxic phathology observed
in some CNS infections and diseases (Barger etal., 2001; Espey et al., 1998; Piani et al.,
1994). On the other hand, analogues that act as blockers of system x^ and limit the
uptake of L-cystine, could also exacerbate excitotoxic damage as a consequence of
attenuating glutathione levels and limiting protection from oxidative damage. Such a
process is consistent with evidence suggesting that oxidative injury and excitotoxicity are
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interacting pathways (Schubert et al., 2001; Trotti et al., 1998; ZLeevalk et al., 1998) and
the direct demonstration that depleting glutathione levels in primary murine cortical cells
enhances the extent of NMDA-mediated excitotoxicity (Bridges et al., 1991).
Although the competition assays provide an effective strategy to delineate the
structural requirements necessary for binding to the substrate domain on the transporter
protein, they provide little or no insight into those characteristics that are required for
actual translocation, i.e., the differentiation of substrates from non-substrate inhibitors.
Traditionally, demonstrating that an analogue acts as a transporter substrate has been
dependent upon either the compound being available as a radiolabeled derivative or using
an alternative analytical method to quantily accumulation, such as HPLC. In the instance
of the Na'-dependent EAATs, the electrogenic nature of the uptake system has allowed
this limitation to be overcome, as substrate-induced currents can be quantified
electrophysiologically (Wadice et al., 1995). Unfortunately in this regard, system x^
appears to be electroneutral. To avoid these labor-intensive alternatives, we identified
putative substrates of system x^ using an approach pioneered by Nicholls and coworkers
(Nicholls et al., 1987) that allows the efflux of L-glutamate from cells to be followed in
real time by coupling its metabolism by glutamate dehydrogenase to the fluorometric
detection of NADPH.
While admittedly semi-quantitative, this approach served well to demonstrate that
the panel of identified inhibitors included both alternative substrates and non-substrate
inhibitors, as well as highlight a number of interesting relationships that distinguish
compounds that only bind to the substrate site on the transporter (and thereby act as
competitive inhibitors) from those that bind and can be translocated. For exanq)le, the
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results demonstrate that conformational restriction does not by itself necessarily produce
non-substrates. Thus, ibotenic acid exhibited similar activi^ to the endogenous substrate
L-cystine, while the acyclic analogue L-serine-O-sulphate proved only about half as
active. Although considerably less active than ibotenate, two closely related
conformationally restricted analogues, 4d)romohomoibotenate and L-quisqualate, also
proved capable of acting as substrates. In addition to illustrating that small structural
changes can substantially influence substrate activity, the demonstration that quisqualate
can directly exchange for intracellular L-glutamate through system

is consistent with

previous HPLC data demonstrating uptake in hippocampal slices and its proposed role in
“quisqualate sensitization” (Chase et al., 2001). Interestingly, those compounds that
proved to be the most potent competitive inhibitors (e.g. L-quisqualate and 4-S-CPG)
also proved to be the least active as substrates, suggesting that distinct structural features
may control binding and translocation. More specifically, the inhibitors exhibiting the
highest affinities may be effectively interacting with domains on the transporter that
promote binding, but preclude the actual translocation of the amino acid. Future studies
will be aimed using the pharmacological profile generated in the present study to increase
the library of active compounds, constructing pharmacophore models for both binding
and transport, as well as develop functional probes with which to elucidate the role of
system x^ in antioxidant protection and excitotoxicity.
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Figure 3.1. Schematic representation of the glutamate dehydrogenase (GDH)
fluorometric assay.
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Efflux of Eglutamate from cells via system x, is quantised by measuring the level of
NADPH fluorescence generated by the metabolism of released L-glutamate by GDH.
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Table 3.1. Ionic dependence of L-cystine induced L-glutamate efflux in SNB-19
glioma cells.

Experiment

Ionic Constitnent

Rate of L-glutamate eHInx
(nmol/min/mg protein)

Total
Cl Free

N aVaNaVGluconate

0.61 ±0.06 (3)
0.46 ±0.02 (3)

Na'' Free

ChohneYCl

1.03 ±0.15 (7)

NaVCl Free

Sucrose

0.42 ±0.02 (3)

Efflux of L-glutamate stimulated by L-cystine (250 mM) from SNB-19 cells was
determined as described in the methods in the presence or absence of the indicated ions.
Values are reported as mean ± S.E.M., (n).
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Table 3.2. Competitive inhibitors of system

exhibit a wide range of substrate

activities as determined by hetero-exchange with intracellular L-glutamate in SNB-19
glioma cells.
Compound

[liM ]

L-Glntamate
Uptake Rate
(pmol/min*mg)

%
Inhibition

L-GIutamate
Exchange Rate
(nmol/min*mg)

% of
Cystine

L-cystine

500

79 ± 13 (6)

88

1.40 ±0.06 (12)

100 ± 4

Ibotenate

300

98 ±11 (6)

86

1.49 ±0.06 (3)

106±4

L-Homocysteate

350

57 ±11 (6)

92

0.84 ± 0.04 (3)

60±5

(RS)-4-Bromohomoibotenate

200

21 ± 3 (6)

97

0.77 ± 0.03 (3)

55 ± 5

L-Serine-O-sulphate

250

89 ± 18 (6)

87

0.72 ±0.05 (3)

51 ± 7

L-Quisqualate

50

115 ±18 (6)

83

0.49 ±0.05 (6)

35± 10

(S)-4-Carboxyphenylglycine

50

129±11(6)

81

0.21 ±0.02(3)

15 ±10

The substrate-induced efflux of L-glutamate from SNB-19 glioma cells by previously
identified competitive inhibitors was determined using the glutamate dehydrogenasebased fluorometric assay described in AfgfAodis. Compounds were tested at
concentrations that produced similar levels of inhibition (88 ± 2% of Control levels) so
that substrate activities were determined at comparable levels of transporter occupancy.
Control uptake for 100 pM L- pH]-glutamate was 680 ± 49 pmol/min mg protein (n =
17). Values are reported as mean ± S.E.M. (n). The rates of L-glutamate exchange have
been corrected for background efflux and are reported as mean ± S.E.M. (n).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

35

Figure 3^. Fluorescence standard curve.
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A) Generation of a fluorescence standard curve in the presence of NADP^ (Im M ) 0 sec,
GDH (33U) 60 sec, and coverslips with sequential 4 nmol injections of L-glutamate
every 200 sec. (B) L-Glutamate standard curve derived from fluorescence data (A).
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Figure 3.3. Baseline and L-cystine- induced L-glutamate efflux.
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(A) Baseline L-glutamate efflux Aom SNB-19 cells in the presence of NADF^ (Im M ) 0
sec, GDH (33 U) 60 sec, with an addition of 0.5% Triton X-100 at 1500 sec. (B) LCyStine induced L-glutamate efflux in SNB-19 glioma cells stimulated by the addition of
500 |iM L-cystine at 600 sec.
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Figure 3.4. 4-S-CPG acts as a non-substrate inWbitor of system

.
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Representative traces are overlayed demonstrating the ability of L-cystine but not 4-Scarboxyphenylglycine to exchange with L-glutamate. Consistent with their action at the
same transporter, 4-S-CPG blocked L-cystine induced exchange when both were
included in the assay. In all experiments exchange was measured in Na^-free HBHS
buffer containing NADP^ (1 mM), GDH (33 U), in presence or absence of L-cystine (500
p ^ , and/or 4-S-CPG (50 pM).
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Chapter 4: The Lathy/w Excitotoxim p-N-Oxalyl-L-a,P-Diammopropionic Acid
(P-L-ODAP) is an Effective Substrate of the L-GIdtamate/L-Cystine Exchanger
System x ,.

Introduction:

p-N-Oxalyl-L-a,p-diamino-propionic acid (p L-ODAP) (also know as L-BOAA,
p-N-Oxalyl amino-L-alanine), found in the seeds of

sativus, is a dicarboxylic

amino acid thought to be an active agent in human lathyrism (Rao, 1964). p-L-ODAP
and the excitatory amino acid L-glutamate share similar chemical structures. With a pKa
of 1.95 and 2.95 on the a and distal carboxyl groups, respectively, and a pKa of 9.25 on
the a amino moiety, p-L-ODAP is an anionic species with a negative one charge at
physiological pH (Rao, 1964). In contrast, p-L-ODAP substitutes an N-oxalyl amide
group at the gamma position and is one carbon longer than L-glutamate. Excessive
consumption of chick peas containing this excitatory amino acid agonist is believed to
cause spastic, irreversible paralysis of the lower limbs (for review see Ludolph etal.,
1987). Males are predominately affected (3:1) following a 2 to 4 month diet containing
50-200 gram/day portions of the chickling pea with a p-L-ODAP content of 1-2%.
vivo studies with macaque monkeys revealed that these primates develop lower limb
paralysis following a one month diet enriched with p-L-ODAP (Spencer et al., 1986).
Discontinuation of p-L-ODAP consumption led to stabilized paralysis with no further
chronic progression. Injection of p-L-ODAP into rat lumbar cerebrospinal fluid causes
distended myelin sheaths with occasional axonal loss in spinal cord sections. This is in
contrast with its isomer a-L-ODAP which proved to be non-toxic (Chase etal., 1985).
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Other in vivo work using mammal models demonstrated that intraperitoneal and oral
administration of p-L-ODAP to adult mice led to neurological damage following CNS
accumulation (Mehta, 1979). In the primary cortex of Aeely moving rats, p-L-ODAP
caused an increase in aspartate that was inhibited by a non-NMDA antagonist and a
glutamate increase that was resistant to inhibiton by the non-NMDA antagonist (La Bella
et al., 2000). Other work in freely moving rats revealed that L-BOAA increased the
production of gangliosides in the hippocampus and decreased production in the olfactory
bulbs (Valdes-Gonzalez et al., 2001).
Electrophysiological studies in cultured fetal mouse spinal neurons, demonstrated
p-L-ODAP to be a non-NMDA agonist since D-AP5 could not block its activity
(MacDonald and Morris, 1984). Later studies in synaptic plasma membranes
demonstrated p-L-ODAP to act potently at quisqualate metabotropic receptors with an
10%= 1.3 pM and less potently at the kainate receptor (ICa,= 17 pM) (Bridges et al,
1989). In guinea pig hippocampal synaptosomes, p-L-ODAP has been fotmd to enhance
L-glutamate release (Gannon, 1989). Using ion-selective microelectrodes, p-L-ODAP
was found to increase Na^ influx and

efflux, with no effect on intracellular Ca^^levels

in Retzius nerve cells (Cemerikic et al., 2001). In addition to its neurotoxic effects, p-LODAP has been shown to be dose dependently toxic to primary cultures of neonatal rat
astrocytes, causing vacuole formation, swelling, and cellular lysis (Bridges et al, 1991).
The interaction of p-L-ODAP with different enzymes has also been reported. In
rat primary astrocyte cultures, p-L-ODAP administration over 24 hours increased
glutamine synthetase activity to 150% of control (Miller et al., 1993). In male mouse
brain slices, p-L-ODAP has been shown to inhibit NADH ubiquinone-1 oxidoreductase
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by thiol modiAcaüon (Sriram et al., 1998). p-L-ODAP was also shown to be a
noncompetitive inhibitor with respect to tyrosine for the liver enzyme tyrosine
aminotransferase in white mice (Vardhan et al.rl997).
P-N-oxalylamino-L-alanine was found to induce cell death in VSC 4.1
motoneuron hybrid cells and immature cortical neurons (La Bella et al., 1996; Murphy et
al., 1990). L-Glutanmte, L-quisqualate, and BOAA-mediated cell death was attenuated in
the presence of 1 mM cysteine in the study by La Bella et al., (1996), while Murphy et
al., (1990) reported that p^S]cystine uptake was inhibited by BOAA. Along with the
other previous sites of action, these results indicate BOAA may be interacting directly
with system x^, System x^ is a heteromeric L-cystine/L-glutamate exchanger which
brings L-cystine into the cell in exchange for L-glutamate. L-Cystine uptake through this
transporter is the rate limiting step in GSH biosynthesis in human Abroblasts (Bannai,
1982).
In the present study, we use selective pH]-L-glutamate uptake assays in SNB-19
glioma cells to delineate the action of p-L-ODAP at system x^. Inhibition of chloridedependent L-glutamate uptake by p-L-ODAP and not by its biochemically inactive
isomers and analogues was fotmd. Kinetic analysis elucidated p-L-ODAP to be a
competitive inhibitor with a K,= 99 ± 12 piM (3). In conjunction, fluorometric assays
indirectly meastmng L-glutamate efflux via system x^ in SNB-19 cells are used to
determine the ability of p-L-ODAP to serve as a substrate, partial substrate, or a non
transportable inhibitor. We report that p-L-ODAP is a competitive inhibitor of system x /
that can serve as a substrate eliciting an L-glutamate efflux that is attenuated in the
presence of the non-transportable inhibitor 4-S-carboxyphenylglycine.
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Results:

P-L-ODAP and N-oxalyl-diamino-dicarboxylic acid analogues were tested for the
ability to interact with system

by measuring their effect on Cl -dependent L-glutamate

uptake in SNB-19 cells. Reported in Table 4.1, p-L-ODAP (500 pM) produced
approximately 81% inhibition in Cl -dependent L-glutamate uptake. This amount of
inhibition is similar to that produced by competitive system x^ inhibitors L-quisqualate
and L-cyStine (500 |iM). The nontransportable inhibitor 4-S-CPG (500 pM) completely
inhibited system

The ability of p-D-ODAP and the a isomers to inhibit Cl -

dependent L-glutamate uptake was much less pronounced and illustrate an enantiomer
specific interaction of P-L-ODAP with system x^'. The ODAB homologues and BMAA
were also found to be relatively inactive as inhibitors. The exact means of this inhibition
was explored in kinetic studies of Cl -dependent L-glutamate uptake presented in Figure
4.1. P-L-ODAP, at concentrations of 60,180, and 300 pM, decreased Cl -dependent Lglutamate uptake in a competitive fashion. As illustrated by the Lineweaver-Burk plot,
Vgua values stayed the same while

^ values increased with increasing concentrations

of P-L-ODAP. For the experiment represented in Rgure 4.1,

and

values of 96 ±

3 and 1029 ± 16 pmols/min mg protein were foimd which are consistent with previously
reported kinetic constants found for Cl -dependent uptake in the SNB-19 cells (mean ±
SEM, n = 4) for L-glutamate of 111 ± 10 pM and 1410 ± 72 pmol/min mg protein,
respectively. A K, was determined by generating a plot of

as a function of [I] and

is represented by the inset in Figure 4.1. The P-L-ODAP/Cl -dependent L-glutamate
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transporter dissociation constant determined for three separate experiments was 99 ± 12
pM.
The fluorometric assay was employed to further elucidate the interaction of P-LODAP with the Cl -dependent L-glutamate transporter. Figure 4 2 illustrates an overlay
of both L-cysdne (250 pM) and P-L-ODAP (250 pM) induced L-glutamate efflux rates in
SNB-19 cells grown on coverslips. Generation of a standard curve by identical means as
represented in Rgure 3.2 allowed the L-glutamate efflux rates to be quantified under each
condition. Following correction for nonspecific L-glutamate efflux, an average of three
separate experiments yielded L-cystine- (250 pM) and P-L-ODAP- (250 pM) induced
chloride-dependent l-glutamate efflux rates of 1.040 ± 0.11(12) and 1.170 ± 0.05 (3),
respectively. At equal concentrations, P-L-ODAP induced a similar L-glutamate efflux
rate as that elicited by the endogenous system x^ substrate L-cystine.
In Rgure 4.3, use of the non-transportable inhibitor 4-S-CPG was used to clarify
whether chloride-dependent P-L-ODAP induced L-glutamate efflux was mediated
through system x, . Upon co-injection of 4-S-CPG with P-L-ODAP and 4-S-CPG with
L-cystine, L-glutamate efflux declined as represented pictorially in panels A and B.
SpeciBc L-cystine- (500 pM) and P-L-ODAP- (370 pM) induced L-glutamate efflux
rates were 1.34 ± 0.07 (15) and 1.20 ± 0.04 (4). Specific L-glutamate efflux rates
declined to 0.36 ± 0.08 (3) for L-cystine (500 pM) + 4-S-CPG (50 pM) and 0.45 ± 0.04
(5) in the presence of p-L-ODAP (370 pM) + 4-S-CPG (50 pM).
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Discussion:

In the present study we directly examine the action of P-L-ODAP at the Cl dependent L-glutamate transporter system x^. We have recently published findings that
the Grade IV human glioblastoma SNB-19 contains two xCT transcripts; xCTa and xCTb
and demonstrated a Cl -dependent L-glutamate uptake activity with a
pmol/min mg protein (n = 4) (Patel et al., 2004).

of 1410 ± 72

The combination of pharmacological

and kinetic data directly show p-L-ODAP to be a competitive inhibitor at system x^ .
Further elucidation in the human glioblastoma cell line revealed the ability of P-L-ODAP
to elicit a Cl -dependent L-glutamate efflux. This EAA analogue (250 pM ) induced an
efflux rate of L-glutamate that was similar to that produced by the system x,. endogenous
substrate L-cystine (250 pM ). This evidence, along with attenuation of substrateinduced L-glutamate exodus in the presence of the system x, non-transportable inhibitor
4-S-CPG, points to the ability of P-L-ODAP to serve as a system x,. substrate. Thus, we
show for the first time the ability of P-L-ODAP to be transported into the cell via system
Xc'.
The activity of P-L-ODAP at the Cl -dependent L-glutamate transporter appears
to be enantiomer specific, with P-D-ODAP only partially inhibiting transport. An
extensive pharmacological screen of N-oxalyl-diamino-dicarboxylie acid analogues at the
Cl -dependent L-glutamate transporter directly shows the specificity of P-L-ODAP at
system x^. Longer chain y homologues and the EAA analogue BMAA proved to be poor
inhibitors. The shorter length a-L-ODAP was also relatively inactive at system x ,.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

44

Interestingly, by boiling the chickling pea during meal preparation, some P-L-ODAP is
converted to its a-isomer, which appears to be non-neurotoxic (Chase et al., 1985).
It is of interest to relate the ability of P-L-ODAP to serve as a system x^ inhibitor
and its ability to mediate toxicity in immature cortical neurons and hybrid motoneuron
cells (La Bella et al., 1996; Murphy et al., 1990). In the study by Murphy et al., (1990),
inhibition of cystine uptake by BOAA produced a high percentage of neuron death. In
findings by La Bella et al., (1996), apoptotic cell death followed incubation of ventral
spinal cord 4.1 cells with P-N-oxalylamino-L-alanine and co-incubaüon of BOAA with
cysteine prevented this outcome. In both studies, incubation with the antioxidant atocopherol attenuated cell death related to cystine transport inhibition. The mechanism of
P-N-oxalylamino-L-alanine toxicity in these two studies is consistent with inhibition of
the cystine/glutamate antiporter system x, leading to depleted intracellular GSH levels
with subsequent oxidative damage and cell death.
Studies in male mouse brain slices show L-BOAA induced oxidation of thiols as
the reason behind lost mitochondrial complex I activity (Sriram et al., 1998). L-BOAA
induced complex I inhibition in motor cortex and lumbosacral slices was reversed by
incubation with the reducing agent dithiothreitol. In the lumbosacral area a significant
reduction in GSH followed L-BOAA mediated-complex I inhibition. These m vivo
results were reversed with the addition of the AMPA receptor antagonist NBQX and the
antioxidant a-lipoic acid. Although L-BOAA may be causing oxidative inhibition of
complex I activity through non-NMDA receptor activation, studies in isolated
mitochondria show L-BOAA to directly inhibit complex I NADH-dehydrogenase activity
without first serving as a EAA receptor agonist (Pai et al., 1993). /n vivo, male mice
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studies revealed L-BOAA induced inhibition of complex I activity in motor cortex and
lumbosacral areas is reversed following upregulation of glutaredoxin (Kenchappa et al.,
2002). Following a single dose of L-BOAA insult, GSH levels drop and pretreatment
with thioltransferase antisense oligonucleotides prevented a reversal of L-BOAA
mediated inhibition of complex I. In order for thioltransferase to activate complex I
activity following L-BOAA mediated insult, GSH levels need to be increased. Following
a single dose of L-BOAA, GSH levels in the motor cortex and lumbosacral cord
decreased. Levels returned to control levels in the motor cortex but remained attenuated
in the lumbosacral cord 24 hours post insult. Under the same conditions, y-glutamyl
cysteine synthetase activity was elevated above control levels in the motor cortex but
arrived back to control levels in the lumbosacral cord 24 hours post L-BOAA insult
(Kenchappa et al., 2003).
Œiotoxicity of EAA analogues p-L-ODAP, L-a-aminoadipate, L-homocysteate,
and L-serine-O-sulphate, but to a much lesser extent by enantiomers, p-D-ODAP, D -aaminoadipate, and D-homocystine, was shown in neonatal Type I astrocytes (Bridges et
al., 1991; Bridges et al., 1992). The lack of action of ionotropic L-glutamate agonists
NMDA, KA, and AMPA indicate the cause of gUotoxicity was not by EAA ionotropic
receptor stimulation. Nuclear swelling with subsequent cellular lysis characterize the
toxic path that was absent in the presence of endogenous amino acids L-glutamate and Laspartate. These transmitters caused only nuclear abnormalities followed by the return to
normal cellular morphology 36-48 hours later. p-L-ODAP caused large vacuole
formation in the astrocytes with similar physical changes found earlier in neurons (Nunn
et a l., 1987).
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In addition to showing that p-L-ODAP is a system x,. substrate we have shown Lhomocysteate, L-serine-O-sulphate, and L-a-aminoadipate to be partial substrates at the
Cl-dependent L-glutamate transporter. It has been proposed that L-a-aminoadipate
serves as a transport system substrate before mediating its gliotoxic actions following
intracellular accumulation (Huck et al., 1984). This action appears to be enantiomer
specific and the metabolism of L-a-aminoadipate minimal. Our studies show the action
of P-L-ODAP at system x,. is also enantiomer specific and others show intracellular
metabolism of the dicarboxylic diamino acid to be negligible (Mehta et al., 1979; Jyothi
et al., 1998)
These findings represent the first, in-depth pharmacological and kinetic
characteristics of the interaction of P-L-ODAP with system x^.

Whether or not P-L-

ODAP- induced pathology in newolathyrism is through direct stimulation of non-NMDA
receptors, its interaction with the chloride-dependent L-glutamate transporter is of
interest. Synaptic clearance and intracellular accmnulation of P-L-ODAP by system x /
may contribute to neurolathyrism in different ways. First, p-L-ODAP can be removed
via transport and its presence in the synapse abbreviated around areas of high system x,
expression. An in .rim hybridization study in mouse brain revealed xCT and 4F2hc
mRNA distribution in the meninges, hypothalamus, and cells surrounding the cerebral
third ventricle (Sato et al., 2002). Immunocytochemical studies using viable antibodies
directed against the system x^ light subunit xCT are still needed to further elucidate these
findings. Secondly, while P-L-ODAP is occupying the system x<. exchanger, cystine
transport by this transporter is attenuated. Cells vulnerable to oxidative damage and
dependent on GSH maintenace through this rate limiting process are susceptible to
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apoptotic and necrotic cell death, /n vitro studies show VSC motoneuron hybrid cells are
dependent on L-cystine uptake by system

whereas primary astrocytes are not (LaBella

et al., 1996; Bridges et al., 1991). Thirdly, due to the lack of P-L-ODAP metabolism,
high levels of intracellular accumulation may occur. This could contribute to cell death
in the CNS in two ways. Firstly, intracellular P-L-ODAP may reach high enough levels
to heteroexchange with extracellular system x, substrates. During this process, p-LODAP would be transported out of the cell and released back into the synapse. A similar
phenonmenon, termed the "quisqualate effect," occurs using the neurotoxic and system
Xg substrate L-quisqualate (Chase et al., 2001). In the course of quisqualate sensitization,
system x^ appears to first remove the neurotoxin from the synapse and initially protect
neurons from excitotoxic damage. Following intracellular accumulation and lack of
metabolism, L-quisqualate may heteroexchange with extracellular substrates through
system x^ and once again be released into the synapse making neurons susceptible to
damage or death through overstimulation of ionotropic L-glutamate receptors. Lastly, PL-ODAP has been shown to directly interact with the enzymes glutamine synthetase,
tyrosine aminotransferase, and NADH dehydrogenase (Miller et al., 1993; Vardhan-Shasi
et al., 1997; and Pai et al., 1993). High intracellular levels of this EAA analogue may
inhibit one or all of these enzymes and cause cell death. The summation of these affects
may play a role in the onset and progression of neurolathyri^.
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Table 4.1. Activity of P-L-ODAP and selected isomers at the Cl -dependent L-glutamate
transporter.

Compound
Control
B-L-ODAP
B-D-ODAP
a-L-ODAP
y-L-ODAB
y-D-ODAB
BMAA
L-Quisqualate
4-S-CPG
L-cystine

[pM]
-

500
500
500
500
500
500
500
500
500

% Control
100±6 (23)
19±1 (3)
77±3 (3)
95±3 (3)
65±3 (3)
70±3 (3)
88±2 (3)
19±1 (3)
0±0(3)
11±1(6)

Uptake of 100 pM L-glutamate under chloride-dependent conditions in SNB-19 cells was
determined as described in Methods. The rates of L-glutamate uptake have been
corrected for non-specific uptake and are reported as mean ± S.E.M. (n).
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Figure 4.1. Competitive inhibition of high-affinity, chloride-dependent, [^H]-L-glutamate
uptake into SNB-19 glioma cells by P-L-ODAP.
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Representative Lineweaver-Burk plot demonstrating (he competitive inhibition of [^H]-L
glutamate uptake into SNB-19 glioma cells by p-L-ODAP. The inset shows a replot of
V.T [P-L-ODAP]. The plots shown were generated using the k-cat kinetic program
(BioMetallics Inc, Princeton NJ) with weighting based on constant relative error, and
yielded values of: Km=96 ± 3 pM,

1029 ± 16 pmol/min mg protein, and

12 pM (K ,.= 99 ± 12 pM (3)).
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Figure 42 . L-cysüne- and P-L-ODAP- induced l-glutamate efflux in SNB-19 cells.
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Overlying fluorometric plots representing L-cystine- and P-L-ODAP- induced Lglutamate efflux rates. Equal concentrations of L-cystine and P-L-ODAP (250 |iM ) were
injected at 6(X) seconds followed by 0.5% Triton X-KX) at 15(X) seconds. Induced Lglutamate efflux rates for the representative L-cystine and P-L-ODAP plots are 0.935
and 1.097 nmols/min mg respectively. Non-specific L-glutamate efflux for the
representative trace is 0.079 nmol/min mg protein.
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Figure 4.3. Attenuation of L-cystine- and P-L-ODAP- induced L-glutamate efflux rates
by 4-S-CPG.
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(A) Representative traces are overlayed demonstrating 4-S-CPG (50 ^M) attenuation of
L-cystine- (500 pM) induced Lrglutamate efflux. Specific rates for the representative
graphs are: L-cystine (500 pM) = 1.25 nmols/min mg protein, L-cystine (500 pM) + 4-SCPG (50 pM) = 0.51 nmols/min mg protein, 4-S-CPG (50 pM) = 0.00 nmols/min mg
protein, and baseline = 0.07nmols/min mg protein. (B) 4-S-CPG (50 pM) attenuation of
P-L-ODAP- (370 pM) induced L-glutamate efflux. Specific rates for the representative
graphs are: P-L-ODAP (370 pM) = 1.29 nmols/min mg protein, P-L-ODAP (370 pM) +
4-S-CPG (50 pM) = 0.58 nmols/min mg protein, 4-S-CPG (50 pM) = 0.00 nmols/min mg
protein, and baseline = 0.07nmols/min mg pilfein. Specific rates for at least three
separate experiments are: L-cystine (500 pM) = 1.34 ± 0.07 (15) nmols/min-mg protein,
P-L-ODAP (370 pM) = 1.20 ± 0.04 nmols/min mg protein (4), 4-S-CPG (50 pM) = 0.17
± 0.05 nmols/min-mg protein (7), L-cystine (500 pM) + 4-S-CPG (50 pM) = 0.36 ± 0.08
nmols/min-mg protein (3), P-L-ODAP (370 pM) + 4-S-CPG (50 pM) = 0.45 ± 0.04
nmols/min-mg protein (5), Non-specific rates = 0.18 ± 0.02 nmols/min-mg protein (28).
In all experiments exchange was measured in Na^-free HBHS buffer containing NADP^
(Im M ) and GDH (33U).
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Chapter 5: Evaluating the Relationship Between System x. A ctivity and
Maintenance of GSH Levels in Human Glioma Cells.

Introduction:

Glutamate transport in the CNS is divided into two high-afRnity systems: the Na^
-dependent transport family system

and the Cl -dependent glutamate/cystine

exchanger system x^. We have studied total L-glutamate uptake in human astrocytoma
cell lines and found that a higher percentage of L-glutamate uptake was mediated through
the Cl -dependent L-glutamate transporter than the Na^-dependent L-glutamate transport
systems. This increased activity of Cl -dependent L-glutamate transport is consistent
with that found in rat and human cells of glioma origin (Cho et al., 1990; Ye et al., 1999).
This increased activity of L-glutamate uptake is consistent with an increased expression
of system x^. This transporter is a cystine/glutamate obligatory exchanger. It is nonelectrogenic and under normal physiological conditions uses a higher intracellular Lglutamate concentration to drive the import of cystine into the cell with subsequent efOux
of L-glutamate from the cell (Bannai, 1982). It is a heteromeric transport system
composed of two subunits: 4F2hc and xCT (Sato, 1999). The regulatory subunit, 4F2hc,
is a glycoprotein containing one transmembrane domain with the light chain, xCT,
containing twelve putative domains. Upon oxidative stress, sytem x,. expression is
upregulated (Bannai, 1984). In the presence of diethyl maleate, an electrophilic agent,
xCT mRNA levels were upregulated in rat and mouse endothelial cells with no change in
4P2hc mRNA levels (Tomi et al., 2002; Hosoya et al., 2002).
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The relationship between Cl -dependent L-glntamate/cystine transport activity and
glutathione (GSH) synthesis is of particular interest. GSH is the major intracellular thiol
in mammalian cells and a key intermediate in a wide range of biochemical processes
(Cooper and Kristal, 1997; Meister, 1995; Meister, 1983). GSH directly conjugates with
various electrophilic drugs and assists in their metabolism and is a protectant from
oxidative damage by acting directly or enzymatically in the neutralization of reactive
oxygen species, free radicals, and electrophiles (Meister, 1991; Shen et al., 1997).
Glutamate, cysteine, and glycine are linked in two separate energy dependent
enzymatically coupled steps to synthesize GSH (Griffith and Meister, 1979).

Of the

three amino acids, intracellular GSH levels appear most dependent upon the availability
of L-cysteine. Transport of extracellular L-cystine or L-cysteine is the predominant
means of providing L-cysteine for GSH synthesis. Due to oxidative conditions in the
extracellular environment, cystine appears to be the primary sulfhydryl amino acid in
culture media, plasma, and CSF (Bannai and Ishii, 1982; Cho and Bannai, 1990; Kranich
et al., 1998).
In certain glioma and neuroblastoma cell lines, maintenance of total intracellular
GSH levels and cell viability are dependent on L-cystine transport by system x^. In the
N18-RE-105 retinoblastoma cells, glutamate and the system x,. inhibitors quisqualate and
ibotenate markedly inhibited L-cystine uptake. Decreased intracellular GSH levels were
subsequently observed, followed by oxidative cell death. These effects were not
mimicked by other EAA ionotropic and metabotropic receptor agonists (Murphy et al.,
1989). In the rat glioma cell line, C6, intracellular GSH levels were depleted in an
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environment with high L-glntamate concentrations and reversed by the addition of
increased L-cystine (Cho and Bannai, 1990).
Using four human astrocytoma/glioblastoma cell lines grown in similar media and
conditions, we explore the relationship between Cl-dependent L-glutamate uptake
activity and maintenance of intracellular GSH levels through system x,. -mediated LcyStine uptake. Our goal is to Rrst identify groups of glioma cell lines that exhibit a
range of Cl -dependent L-glutamate uptake activity and determine total intracellular GSH
levels (GSH + GSSG) in these cells when grown under identical conditions. Our kinetic
findings showed an approximate five fold range in system x,. activity among these cells.
The SNB-19 cell line, which expressed the highest Cl -dependent L-glutamate uptake
activity, also exhibited the highest total intracellular GSH concentration. All four tumor
cell lines had very similar relative rates of GSH turnover based upon inhibition of
glutathione synthesis with the y-glutamylcysteine synthetase inhibitor L-buthionine[SR]-sulfoximine. However, GSH levels were not equally decreased by the system x,
inhibitor, 4-S-carboxyphenylglycine. Thus, the GSH pools in all of the tumor cell lines
may not be similarly dependent on L-cystine uptake by system x^, but may express
alternative transport systems to provide the GSH rate limiting precursors L-cystine or Lcysteine.

Results:

Detailed kinetic analyses quantifying Cl -dependent [^H]-L-glutamate transport
activity (equimolar substitution of Na^ with choline) in four glioma cell lines were
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performed and corrected for non-speciRc uptake by substracting the amount of
glutamate accumulated at 4 °C. Lineweaver-Burk plots and associated kinetic parameters
were estimated by computer analysis using the k.cat kinetic program (BioMetallics Inc.)
with weighting based on constant relative error and reported in Table 5.1 (mean ± SEM,
n = 4). We first reported

and

values for Cl -dependent [^H]-L-glutamate

transport in SNB-19 cells in a previous study (Patel etal., 2004). A student t-test
revealed a statistically higher (p <0.01)
and a statistically higher

value for SNB-19 cells relative to the others

(p <0.01) for U-373 #elative to the three other tumor cell

lines. Vgug values amongst the U-373, SW-1088, and CCF-STTGl cell lines show slight
variances, but were not statistically different (p > 0.05). A comparison of SNB-19, SW1088, and CCF-STTGl Kg, values also revealed no difference (p > 0.05).
The DTNB-based recycling assay of Tietze (1969) with modifications by Griffith
(1980) and Anderson (1985) was used to assay total intracellular GSH (GSH + GSSG)
concentrations in the four human glioma cell lines. Cells at 90 to 95% confluency and
grown under similar media and conditions were harvested and total intracellular GSH
levels determined. Values are reported in Figure 5.1 as mean (nmols/mg protein) ± SEM
(n). Total intracellular GSH levels in SNB-19 cells are, 67 ± 3 (22), a value statistically
higher (p <0.01) than total GSH levels detected in the other three cell lines. The CCFSTTGl cells exhibit the second highest intracellular GSH levels of 55 ± 3 (19), and are
statistically different (p <0.01) from the SW-1088 = 38 ± 2 (19) and U-373 = 34 ± 2 (20).
No difference was fotmd between total intracellular GSH levels in the SW-1088 and U373 cells.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

57

The effect of increased extracellular levels of rate limiting precursors L-cystine
(250 and 500 ;/M ) and L-cysteine (500 /fM and 1 mM) on total intracellular GSH levels
in four human glioma cell lines was evaluated and presented in Rgure 5.2 as mean
(nmols/mg protein) ± SEM (n). Media changes were performed every three to four days.
Control L-cystine and L-cysteine concentrations in the growth media on these days were
100 and 125 /fM respectively. At the beginning of the incubation period when cells were
90 to 95% confluent, L-cystine or L-cysteine were added to designated wells without a
media change and the cells were harvested 24 hours later. Neither concentration of Lcystine produced a statistical rise in total intracellular GSH levels while L-cysteine (500
[iM) statistically raised SNB-19 levels (p <0.01). This suggests that L-cystine was
present in the media at a saturating level relative to GSH synthesis in the control
conditions. The ability of L-cysteine (500 /fM ) to increase intracellular total GSH levels
in the SNB-19 cells may indicate that the 125 ;^M concentration of this amino acid under
control media conditions is not at a saturating concentration and intracellular GSH levels
in this cell line may be effected by L-cysteine levels.
A time course study evaluating GSH turnover in the four cell lines using the yglutamylcysteine synthetase inhibitor L-buthionine-[SR]-sulfoximine (500 /fM ) was
performed. Values are reported in Figure 5.3 as mean % of control ± SEM. BSO
irreversibly inhibits the enzyme y-glutamylcysteine synthetase. At the beginning of the
incubadon period, BSO (500 ;<M) was added to designated wells without a media change
and cells were harvested at the indicated time points. Following the 24 hour time course,
total intracellular GSH levels were similarly reduced to approximately 10% of control in
the SNB-19, CCF-STTGl, and U-373 cells. Levels were decreased statistically lower (p
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<0.05) relative to the other three cell lines in the SW-1088 cells to approximately 5% of
control.
The contribution of other amino acid transporters to the maintenance of total
intracellular GSH levels was evaluated using inhibitors at concentrations estimated to
inhibit transport by 80-90% estimated from literature

values. The inhibitors included:

system x, inhibitor 4-S-carboxyphenylglycine (4-S-CPG), system x^^g inhibitor L-trwwpyrrolidine-2,4-dicarboxylic acid (L-T-2,4 PDC), system ASC inhibitor L-N^-Pchlorophenyl-glutamine (L-N.,-PCP-G), and system L inhibitor 2-amino-2-norbomanecarboxylic acid (BCH). Values are shown as mean % of control ± SEM and are
displayed in Figure 5.4. At the beginning of the incubation period when cells were 9095% confluent, the transporter blockers were added to designated wells without a media
change and cells were harvested following a 24 hour incubation period. In all four cell
lines, 4-S-CPG significantly reduced total intracellular GSH levels relative to control (p <
0.01). Interestingly, SNB-19 GSH levels following the 24 hour incubation period in the
presence of 4-S-CPG (250 //M ) were stadsdcaUy greater than GSH levels in the three
other cell lines under the samb conditions (p <0.01). The other three transporter blockers
had no significant effect on tot^ intracellular GSH levels.
In order to further elucidate the role of system x,, in the maintenace of total
intracellular GSH levels in (he four human glioma cell lines, a time course study using
the non-transportable inhibitor 4-S-CPG was performed. Values are reported in Figure
5.5 as mean % of control ± SEM. At the beginning of the incubation period, 4-S-CPG
was added to designated wells without a media change and cells were harvested at 2,6,
12, and 24 hour time points. Following the 24 hour incubation period, total intracellular
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GSH levels in the SNB-19 cells incubated with 4-S-CPG were approximately 40% of
%

control. 4-S-CTG depleted total intracellular GSH levels in the CCF-STTGl and U-373
to approximately 20% of control and levels in the SW-1088 to approximately 15% of
control . Total SNB-19 intracellular GSH levels 24 hours post a 4-S-CPG (250 ;^M)
incubation time were statistically higher (p <0.01) than intracellular levels found in the
other three cells following a 24 hour period in the presence of 4-S-CPG (250 ;^M).
Following the same 24 hour incubation period with 4-S-CPG (250 /^M), SW-1088 total
intracellular GSH levels were slightly lower than CCF-STTGl levels (p <0.05). No other
differences were found in total intracellular GSH levels between the cell lines following
the 24 hour 4-S-CPG (250 ;<M) insult.
The ability of L-cysteine or L-cystine to rescue total intracellular GSH levels
following system x^ transporter- mediated inhibition with 4-S-carboxyphenylglycine is
evaluated in Table 5.2. Values are represented as mean % of control ± SEM (n). Media
changes were performed every three to four days. Control L-cystine and L-cysteine
concentrations in the added growth media were 100 and 125 ;<M respectively. At the
beginning of the incubation period, when cells were 90 to 95% confluent, 4-S-CPG and
4-S-CPG with the amino acids L-cysteine or L-cystine were added to designated wells
without a media change to give a total maximal concentration for the compounds of that
listed in the table. Total GSH levels in all four cell lines in the presence of L-cystine
(500 ;<M) + 4-S-CPG (250 ;<M) were statistically higher (p <0.01) than GSH levels found
solely in the presence of 4-S-CPG. In the presence of L-cysteine (500 /fM ) + 4-S-CPG
(250 /iM ), GSH levels were statistically higher (p <0.05) in the SNB-19 cells relative to
the total intracellular GSH levels found in the CCF-STTGl and SW-1088 under the same
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conditions. This once again illustrates that total intracellular GSH levels in the SNB-19
cells may be effected by L-cysteine uptake.
In order to determine if total GSH levels in the SNB-19 cells can be further
decreased, total intracellular GSH levels were measi^pd in the presence of 4-S-CF*G in
combination with other transporter blockers. Values are reported as mean % of control ±
SEM and displayed in Figure 5.6. At the beginning of the 24 hour incubation period, 4S-CPG and 4-S-CPG with the amino acid transporter blockers: L-T-2,4 PDC, L-N^-PCPG, or BCH were added to designated wells without a media change to give a total
concentration of compounds as that listed in the inset. Total intracellular GSH levels
were statistically less (p <0.05) following a # 4 hour incubation period in the presence of
4-S-CPG + L-Ny-PCP-G relative to total GSH levels found solely in the presence of 4-SCPG. When comparing the total intracellular GSH levels in the SNB-19 cells following
the incubation period with 4-S-CPG + L-N^-PCP-G with total intracellular GSH levels in
the other three cell lines following a 24 hour incubation with 4-S-CPG, there is no
statistical difference in reduced total GSH levels (p <0.05).

Discussion:

The system

transporter initially characterized on human fibroblasts is a Cl -

dependent, Na^-independent electroneutral exchanger of L-cystine and L-glutamate
(Bannai and Kitamura, 1980; Bannai, 1986). Composed of two subunits, xCT and 4F2hc,
this transport protein is a heteromeric exchanger belonging to the glycoprotein-associated
amino acid transporter (gpaAT) family (Verrey et al., 2000). Cl -dependent uptake of
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[^H]-glutamate is a marker of system x, activity and was used by our lab to elucidate the
kinetic and pharmacological properties of this uptake system in two CNS-derived tumor
cell lines, LRM-55 and SNB-19 (Patel, 2004). In this study we found the Group I
metabotropic receptor antagonist, 4-S-carboxyphenylglycine (4-S-CPG) to be a potent
competitive inhibitor and non-transportable substrate of the cystine/glutamate obligatory
exchanger.
A series of human glioma cell lines grown in similar media and conditions were
characterized for Cl -dependent L-[^H]-glutamate uptake to quantify system x^ activity
levels. By generating Lineweaver-Burk plots and obtaining the kinetic constants,

and

Vggg, some relative comparisons are made. An approximate Rve-fold range in system
Xg activity is apparent between CCF-STTGl and SNB-19 cells by comparing

values.

These findings are consistent with other reports which show increased levels of Cl dependent L-pH]-glutamate uptake in CNS-derived tumor cell lines relative to nonmetastatic cells (Murphy et al., 1989; Waniewski and Martin, 1984). The exploitation of
this biochemical difference may prove useful in future cancer therapy. Thus the
physiological relevance between these varying levels of system x, activity and
maintenance of intracellular GSH levels is of particular interest.
The DTNB-based recycling assay was used to determine total intracellular GSH
(GSH +GSSG) concentrations in the four human glioma cell lines exhibiting a range of
system x, activity. Cells at 90 to 95% confluency and grown under similar media and
conditions were harvested and total intracellular GSH levels detected. The SNB-19 cell
line, which expresses the highest Cl -dependent L-glutamate activity, has nearly double
the concentration of total intracellular GSH levels (67 ± 3 (22)) relative to the SW-1088
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and U-373 cells (38 ± 2 (19) and 34 ± 2 (20) respectively) and a statistically greater (p <
0.01) portion relative to CCF-STTGl levels (55 ± 3 (19)). Despite the range in total
GSH values, these cell lines show similar percentage changes in the intracellular thiol
when GSH biosynthesis is block^ with BSO (Figure 5.3).
We studied the contribution of the cystine/glutamate exchanger in maintaining
intracellular GSH levels in the tumor cells by using the system x^ non-transportable
inhibitor 4-S-CPG and observing the changes in total intracellular GSH levels following a
24 hour incubation period. 4-S-Carboxyphenylglycine statistically lowered (p <0.01)
total intracellular GSH levels in the four cell lines (Figure 5.4). A time course study with
4-S-CPG revealed total intracellular GSH levels in the SNB-19 cell line to be least
dependent upon system x^ activity (Figure 5.5). Increasing intracellular GSH
concentrations by supplementing L-cystine levels supported the notion that 4-S-CPG was
causing its effect through inhibition of system x, (Table 5.2). Our findings indicate that
maintenance of intracellular GSH levels in the CCF-STTGl, SW-1088, and U-373 is
heavily dependent upon L-cystine uptake by system x^. To our surprise we found that
even though the SNB-19 cells express the highest amotmts of system x, activity relative
to the three other cell lines grown in a similar environment, total intracellular GSH levels
in this glioblastoma cell line are the least dependent on L-cystine uptake by this
transporter. This raises two interesting questions. The first is that in addition to LcyStine uptake by system x^, what other transport system or systems may be providing
precursors for GSH biosynthesis in the SNB-19 cells? We address this question
experimentally. The second is what other physiological functions may system x,
perform in vivo? This question is speculated upon below.
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System

- mediated L-glutamate release from glioma cell lines in vifro is of

particular interest. Over a twelve hour incubation period, the human astrocytoma cell
line STTG-1 increased extracellular L-glutamate levels in culture from approximately
100 pM to 400 pM, whereas primary astrocytes depleted L-glutamate levels from 92 to 1
pM (Ye and Sontheimer, 1999). The STTG-1 release of L-glutamate was inhibited in a
dose-dependent manner W the system

nontransportable inhibitor 4-S-CPG.

Conversely, the endogenous system x, substrate L-cystine stimulated L-glutamate release
in a dose- and time- dependent manner (Ye et al., 1999). In a glioma-neuronal coculture,
disintegrated neurons were found 36 hours after coculture. Following an identical
coculture trial in the presence of 4-S-CPG or the NMDA-specific inhibitor MK-801,
neuronal cell death was prevented (Ye and Sontheimer, 1999). This suggests that the
massive amounts of L-glutamate released through system x, may be a mode of gliomamediated neurotoxicity (Sontheimer, 2003).
vitro and in vivo growth and migration studies were done on glioblastoma cells
expressing Ca^-permeable AMPA receptors (Ishiuchi et al., 2002). fn vitro migration
using the cell line CGNH-89 expressing Ca^^-permeable AMPA receptors was found
while the CGNH-89 cells transgenically programmed to express Ca^^- impermeable
AMPA receptors showed retarded métastasés. Nude mice injected with the wild type and
transgenic cells revealed similar findings (Ishiuchi et al., 2002). Thus, L-glutamate
activation of these Ca^-permeable AMPA receptors appears to play a key role in the
metastatic nature of these neoplastic cells. The origin of L-glutamate to induce this
change is not known. Interestingly, in vivo findings in rats revealed that the main source
of nonvesicular L-glutamate release into the nucleus accumbens is by system x^ (X i et
al., 2002; Baker et al., 2003). These findings and others may indicate that human glioma
cells can advantageously release copius amounts of L-glutamate through system x^. This
l-glutamate may kill surrounding neurons opening up new niches for tumor cell growth
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while sending an autocrine message for tumor spread through activation of Ca^*permeable glutamate receptors (Sontheimer, 2003).
In addition to cystine transport by system

, three other transport systems may

contribute the rate limiting precursors, L-cysteine or L-cystine, for GSH synthesis. The
Rrst, system L , has been shown to transport L-cysteine in mammalian cells (Bannai et
al., 1984; Knickelbein et al., 1997). The second, system Xy^g, is a Na^-dependent Lglutamate transport family composed of rive subtypes EAAT 1-5 (Danbolt, 2001).

In

rat alveolar II cells and cultured astrocytes, system Xy^^ was shown to transport L-cystine
(Knickelbein et al., 1997; Bender et al., 2000). Interestingly, studies have shown a
reduction and mislocalization of sodium-dependent glutamate transporters in a series of
human glioma cells (Ye et al., 1999). The third, system ASC, predominately transports
the amino acids alanine, serine, and cysteine and belongs in the same solute carrier gene
family (SLC l) as system Xy^q (Kanai et al., 2001). The observed upregulation in system
ASC expression in rat glioma and human neuroblastoma cells is of particular interest
(Wasa et al., 2002; Dolinska et al., 2003).
In the four glioma cell lines, we studied the potential contribution that these three
transport systems may play in GSH maintenace (Figure 5.4). No changes in GSH levels
was observed. However, using die system ASC inhibitor L-Ny-PCP-G, we Rnd a
statistically significant decline in SNB-19 GSH levels determined in the presence of LNy-PCP-G+4-S-CPG relative to GSH levels observed in the presence of 4-S-CPG (Figure
5.6). We also show the significant rise in SNB-19 intracellular GSH levels in the
presence of increased L-cysteine levels (Figure 5.2). In addition to L-cystine transport by
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system x ,, these Rndings may point to the ability of SNB-19 cells to provide the ratelimiting precursor L-cysteine by another transport system; system ASC.
System ASC is the predominant L-cysteine transporter found in a neuronal culture
(Sagara et al., 1993). GSH levels in these cells could not be maintained by extracellular
L-cystine but instead, only by gUal released L-cysteine (Sagara et al., 1993). In another
study, intracellular GSH levels in rat primary neuronal cells were found to be maintained
by transport of extracellular L-cysteine (Kranich et al., 1996). The SNB-19 cell line
appears to mirror these findings by possessing an alternative transporter for the GSH
precursor L-cysteine. It is interesting to speculate that in addition to supplementing its
own GSH reservoirs, SNB-19 cells may be able to clear glial-released L-cysteine from
the synapse and thereby starve neurons from GSH precursors. Neuronal cells appear to
be more vulnerable to oxidative damage and this transport of L-cysteine into SNB-19
cells may decrease GSH levels in proximal neurons leaving them susceptible to apoptotic
or excitotoxic death.
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Table 5.1. Varying levels of Cl -dependent L-glutamate transport rates in human glioma
cells grown under similar conditions.

Cell Line

Vn^(pmok/min mg protein)

Km(KM)

SNB-19

1410 ± 72 (n=4)

111 ± 10 (n=4)$

U-373

553±116(n=4)*

177 ± 8 (n=4)

SW-1088

437 ± 79 (n=4)*

109 ± 6 (n=4)$

CCF-STTGl

349 ± 65 (n=4)*

104 ± 14 (n=4)$

Results are reported as mean ± SEM for at least four separate experiments
conducted in duplicate and are corrected for non-specific uptake (e.g., leakage and
binding) by substracting the amount of pH]-L-glutamate accumulated at 4 °C. Both
specific and non-speciEc transport rates were determined in the presence of Cl and
absence of Na^ (equimolar substitution with choline). Lineweaver-Burk plots and
associated kinetic parameters were estimated by computer analysis using k.cat kinetic
program (BioMetallics Inc.) with weighting based on constant relative error (refer back to
Rgure 4.1 p. 49). * Denotes values significantly less than SNB-19 Cl -dependent Lglutamate transport rates, p <0.01; $Denotes Kg, values signiEcantly less than U-373
values, p <0.01.
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Figure 5.1. Varying amounts of total intracellular GSH levels in four human glioma cell
lines grown under similar conditions.
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Total intracellular glutathione levels (GSH + GSSG) were determined through a
recycling assay and are reported as nmols/mg protein ± SEM (n) in cells 90 to 95%
confluent grown in identical media and conditions. Data for each determination was
based on 13-16 separate experiments in which total GSH levels were measured from
single wells in duplicate. GSH levels are as follows: SNB-19 = 67 ± 3 (22), CCFSTTGl = 55 ± 3 (19), SW-1088 = 38 ± 2 (19), and U-373 = 34 ± 2 (20). *Denotes values
significantly less Aan SNB-19 intracellular GSH levels, p <0.01; $Denotes values
significantly less than CCF-STTGl inhacellular GSH levels, p <0.01.
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Figure 52. Total intracellular GSH amounts are minimally raised in the presence
of increasing L-cystine and L-cysteine levels.
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Total intracellular glutathione levels (GSH 4- GSSG) were determined through a
recycling assay and are reported as nmols/mg protein ± SEM (n) following a 24 hr.
incubation period. Data for each determination was based on at least three separate
experiments in which total GSH levels were determined in duplicate. Media changes
were performed every three to four days. Control L-cysdne and L-cysteine
concentradons in the growth media on these days were 100 and 125 ;/M respecdvely. At
the beginning of the incubadon period when cells were 90 to 95% confluent, L-cysdne or
L-cysteine was added to designated wells without a media change to give a maximal
concentradon of that listed for the amino acids in the inset and the cells were harvested
24 hours later. * Denotes values significantly greater than control GSH values, p <0.01.
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Figure 5.3. GSH levels are similarly reduced in the tumor cell lines by the yglutamylcysteine synthetase inhibitor BSO.
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Total intracellular glutathione levels (GSH + GSSG) were determined through a
recycling assay and are reported as % of control ± SEM (n) following a time course study
on cells 90-95% confluent. Data for each determination was based on at least three
separate experiments in which total GSH levels were determined in duplicate. Control Lcystine and L-cysteine concentrations in the growth media were 100 and 125 pM
respectively. At the beginning of the 24 hr incubation period, BSO (500 pM ) was added
to designated wells without a media change and cells were harvested at the following
time points. * Denotes a value signiAcantly less than GSH amounts found in the SNB-19,
CCF-STTGl, and U-373 at the 24 hr. time point in the presence of BSO (500 pM ), p <
0.05.
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Figure 5.4. Total intracellular GSH levels precipitously drop in the presence of the
system

non-transportable inhibitor.
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Total intracellular glutathione levels (GSH + GSSG) were determined through a
recycling assay and are reported as % of control ± SEM (n) following a 24 hr incubation
period on cells 90-95% confluent. Data for each determination was based on at least
three separate experiments in which total GSH levels were determined in duplicate.
Control L-cystine and L-cysteine concentrations in the growth media were 100 and 125
pM respectively. At the beginning of the 24 hr incubation period, amino acid transporter
blockers were added to designated wells without a media change to give a total inhibitor
concentration of that listed in the inset. * Denotes values significantly less than control
GSH values, p <0.01. $Denotes values significantly greater than total GSH (GSH +
GSSG) amounts found in the other three cell lines in the presence of 4-S-CPG (250 pM ).
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Figure 5 .5. Total intracellular GSH levels are dropped to varying degrees following
administration of the system x, inhibitor 4-S-CPG.
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Total intracellular glutathione levels (GSH 4- GSSG) were determined through a
recycling assay and are reported as % of control ± SEM (n) following a time course study
on cells 90-95% confluent. Data for each determination was based on at least three
separate experiments in which total GSH levels were determined in duplicate. Control Lcystine and L-cysteine concentrations in the growth media were 100 and 125 pM
respectively. At the beginning of the 24 hr incubation period, 4-S-CPG (250 pM ) was
added to designated wells without a media change and cells were harvested at the
following time points. * Indicates a value significantly greater than intracellular GSH
levels found in the other three cell lines at the 24 hour time point, p <0.01.
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Table 5.2. Replenishment of total intracellular GSH levels with increasing Lcysteine and L-cystine amounts during transporter-mediated insult with 4-S-CPG.

Control
4-S-CPG (250 pM)
4-S-CPG (250 pM)

Total Intracel ular Glutathione ^vels (% of control)
U-373
CCF-STTGl
SW-1088
SNB-19
100 ± 6 (20)
100 ± 4 (22) 100 ± 5 (19)
100 ± 5 (19)
18 ± 3 (14)
20 ± 2 (13)
13 ± 3 (12)
40 ± 3 (16)
78 ± 2 (3)** 58 ± 2 (3 )**,$ 47 ± 8 (3 )**,$ 53 ± 18 (3)

4-

L-cysteine (500pM)
4-S-CPG (250 pM)

81 ± 6 (5 )**

80 ± 9 (5 )**

7 4 ± 1 3 (5 )**

62 ± 12 (6)**

4

■ -

L-cystine (500pM)
Total intracellular glutathione levels (GSH + GSSG) were determined through a
recycling assay and are reported as % of control ± SEM (n) following a 24 hr incubation
period on cells 90-95% confluent. Data for each determination was based on at least
three separate experiments in which total GSH levels were determined in duplicate.
Control L-cystine and L-cysteine concentrations in the growth media were 100 and 125
pM respectively. At the beginning of the 24 hr incubation period, 4-S-CPG and 4-S-CPG
with the amino acids L-cysteine or L-cysdne were added to control media in designated
wells to give a total concentration of that listed in the table. **Denotes values
significantly greater than 4-S-CPG (250 pM) GSH amounts, p <0.01. ^Denotes values
significantly less than SNB-19 GSH levels found in the presence of 4-S-CPG (250 pM ) +
L-cysteine (500 /<M), p <0.01.
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Figure 5.6. Total intracellular GSH levels are further reduced following
administration of the system ASC cellular amino acid transporter blocker with 4-SCPG in the SNB-19 cell line.
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Total intracellular glutathione levels (GSH -i- GSSG) were determined through a
recycling assay and are reported as % of control ± SEM (n) following a 24 hr incubation
period on cells 90-95% confluent. Data for each determination was based on at least
three separate experiments in which total GSH levels were determined in duplicate.
Control L-cystine and L-cysteine concentrations in the growth media were 100 and 125
pM respectively. At the beginning of the 24 hr incubation period, 4-S-CPG and 4-S-CPG
with the amino acid transporter blockers: L-T-2,4 PDC system XAo, L-N^-PCP-G system
ASC, or BCH system L were added to designated wells without a media change to give a
total concentration of that listed in the inset. *Denotes values significantly less than
GSH values found in the presence of solely 4-S-CPG, p <0.05.
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Chapter 6: Conclusions:

The work presented in this thesis furthers our understanding of system x, and
leads to many exciting questions. The first portion of this study presents an experimental
technique that allows the cellular efflux of L-glutamate through system x^ to be followed
in real time by coupling its metabolism by glutamate dehydrogenase to the fluorometric
detection of NADPH. This approach provides an effective strategy to delineate the
structural requirements necessary for substrate transport (i.e. translocation) in contrast to
the competition assays, which provide insight only on the process of binding. The
finding that acyclic glutamate analogues, L-homocysteate and L-seiine-O-sulphate are
partial substrates at system x^ also raises some interesting questions. These compounds
both have sulfur containing moieties replacing the distal carboxylate and this anionic
group substitution may be a strategy to synthesize more effective substrate/inhibitors.
Interestingly, the two most potent competitive inhibitors, L-quisqualate and 4-S-CPG,
were found to be the least active as substrates. These compounds are both cyclic
glutamate analogues whose function at the transporter contrasts sharply with the system
Xg substrate ibotenate. These Andings may prove useful in computer-based molecular
modeling studies aimed at generating substrate and non-substrate inhibitor
pharmacophores.
The results of this dissertation may also aid in the development of future glioma
therapeutic strategies. Thus the ability to deliver cytotoxic or imaging agents to tumor
cells via system x^ could prove beneficial, as could GSH (GSH4GSSG) depletion and
subsequent radiosensitization through cystine transport inhibition. System x /
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upregulation in CNS-derived tumor cells relative to expression levels in primary
astrocytes is a biochemical process that could be manipulated to specifically target
glioma cells in vivo. Knowledge of an inhibitor pharmacophore of system x^ could be
used to synthesize compounds directed at blocking the cystine/glutamate obligatory
exchanger. This may attenuate the transport of needed amino acids (i.e. L-cystine) and
make the tumor cells more vulnerable to radiation- or chemotherapy- based treatments.
Details of a system x^ substrate pharmacophore could be used to synthesize fluorescent
or radioactive imaging agents to quantify the amount and location of metastatic tumor
growth in the CNS. Also, cytotoxic compounds could be generated that serve as system
Xg substrates which prove lethal to glioma cells once transported inside.
In the second portion of work, P-N-oxalyl-L-a,p-diaminopropionic acid (P-LODAP), a non-protein glutamate analogue believed to be the causative agent underlying
the motor nemon degeneration and spastic paraparesis in human neurolathyrism was
studied. It is believed that thé interaction of P-L-ODAP with EAA receptors is a
causative factor in the progression of neurolathyrism. However, our studies and others
have shown that this non-protein amino acid interacts at other sites and the sum of its
actions may contribute to its pathological properties. In order to define the interactions of
P-L-ODAP with system x ,, the radiolabel-uptake and fluorometrically- coupled assays
were used. P-L-ODAP was found to not only be a competitive inhibitor, but to also
exhibit substrate activity comparable to that of the endogenous substrate L-cystine.
These findings and the observations that P-L-ODAP has the ability to specifically destroy
neurons in certain regions of the spinal cord (e.g. ventral horn cells around the thoracic
pyramidal tract) raises some interesting questions. The abili^ of system x^ to transport
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and accumulate P-L ODAP could limit its access to EAA receptors. It may be of interest
to define regions of system

expression through immunocytochemisty studies. With

the generation of antibodies specific for the xCT subunit this analysis may be possible.
Once accumulated in certain cells, p-L-ODAP would also have access to intracellular
targets. It may be of interest to specifically define targets (e.g. enzymes or receptors)
inside cells that makes neurons and glia vulnerable to P-L-ODAP- mediated
pathogenesis.
Lastly, we investigated the relationship between levels of system x^ activity and
the maintenance of intracellular glutathione concentrations in several glioma- derived cell
lines. Using the chloride-dependent L-fH]-glutamate radiolabel- uptake assay, we
demonstrate high levels of system

activity in the four CNS- derived tumor cell lines.

Using the GSH recycling assay, we were able to determine total intracellular GSH levels
and elucidate possible physiolological roles that system x^ may play in maintaining this
intracellular thiol. By comparing the effect of system x^ inhibitors, such as 4-Scarboxyphenylglycine, with other inhibitors of glutathione biosynthesis, such as
buthionine sulfoximine, on glutathione levels, the contribution of the transporter in
supplying extracellular precursors for this antioxidant could be estimated. We observed
that inhibition of system x^ led to a time- dependent decrease in intracellular glutathione
levels. However, we also found that the levels of system x^ activity varied among the
cell lines, even though the rates of glutathione utilization appeared similar. These results
suggest that the amount of cystine transported through this system may not always be a
rate limiting factor in glutathione homeostasis. It may be of interest to extend these
findings to cell survivability studies to determine if GSH depletion has varying levels of
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impact on cell survival in the four glioma lines. This may include observing whether
cells are made more sensitive to radiation or chemotherapeutic insult following system
inhibition and subsequent GSH depletion.
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